

FINAL PROGRAM



WORLD CONGRESS ON PARKINSON'S
DISEASE AND RELATED DISORDERS

CHICAGO, USA

2023

13 – 16 May

www.iaprd-world-congress.com



TABLE OF CONTENTS

Welcome

Acknowledgement	04
Welcome Message	05

Scientific Program

Floorplan	08
Session Descriptions and Types	09
Saturday, 13 May 2023, Program Overview	10
Saturday, 13 May 2023, Scientific Program	11
Sunday, 14 May 2023, Program Overview	14
Sunday, 14 May 2023, Scientific Overview	15
Monday, 15 May 2023, Program Overview	20
Monday, 15 May 2023, Scientific Overview	21
Tuesday, 16 May 2023, Program Overview	28
Tuesday, 16 May 2023, Scientific Overview	29
Poster Exhibition	31
Information for Abstract Authors	45
Information for Speakers	45
Travel Grants	45
Index of Authors and Speakers	46

General Congress Information

Registration	50
CME Accreditation	51
Congress Venue	52
Good to know	54

IAPRD

About the International Association of Parkinsonism and Related Disorders	58
IAPRD Committees	60

Industry

Exhibition Floor Plan	64
List of Exhibitors	64
Sponsors and Supporters	65
Corporate Sessions	66
Imprint and Data Protection	70

ACKNOWLEDGEMENT

IAPRD thanks the following organizations for their support of the XXVIII World Congress on Parkinson's Disease and Related Disorders in Chicago, United States.



WELCOME WORDS

Welcome to IAPRD 2023 in Chicago, United States of America

On behalf of the International Association of Parkinsonism and Related Disorders (IAPRD), it is our pleasure to welcome you to the XXVIII World Congress on Parkinson's Disease and Related Disorders.

Thank you for joining us in Chicago, a bustling city on the southwestern shore of Lake Michigan. Chicago is known for its walkable parks, iconic architecture, world-class museums, and award-winning dining that you won't want to miss!

The IAPRD 2023 Congress features a comprehensive program in movement disorders led by a global faculty in support of the theme Evolving the Treatment Paradigm in Movement Disorders. We hope you gain insights from the presentations and enjoy ample time to exchange ideas with colleagues.




Cynthia Comella, MD
Congress Chair



Rajesh Pahwa, MD
SPEC Chair



Daniel Truong, MD
President IAPRD



Alberto Albanese, MD, PhD
President Elect IAPRD



SCIENTIFIC PROGRAM

FLOOR PLAN



SESSION DESCRIPTIONS AND TYPES



PLENARY SESSIONS

These sessions will include lectures on phenomenology, pathophysiology, diagnostic and therapeutic approaches to various movement disorders. Each lecture within a plenary theme will be 30 minutes, delivered by world-renowned senior faculty members.



PARALLEL TRACKS

The sessions within a track are arranged to provide a deep dive into a diagnostic or therapeutic area. Each lecture will be 30 minutes (25 minutes of didactic followed by 5 minutes of Q and A).



GRAND PARADE OF MOVEMENT DISORDERS

A video session where both faculty and attendees present pre-selected cases from around the globe to showcase the breadth of movement disorders. This event will be co-hosted by several of our most astute and experienced clinical experts.



COFFEE WITH THE PROFESSOR

There are brief mentoring sessions sprinkled throughout the duration of the congress where young and aspiring clinicians and scientists can engage with a renowned faculty member, in a relaxed setting, over a cup of coffee.



CORPORATE SESSIONS (over Lunch)

These sessions, sponsored by our industry partners, will be held during lunchtime.



ORAL POSTER SESSIONS

Poster authors are expected to present their poster and answer questions from the moderator as well as from the audience of the Oral Poster Session. The author or presenter must be registered for the congress.



RESIDENT AND TRAINEE PROGRAM








Shorter, classroom-style educational sessions.

PROGRAM OVERVIEW / SATURDAY, 13 MAY 2023

SATURDAY, 13 MAY 2023

Room ▶	Plenary Room W196	Room W194b	Room W192a	Room W192b	Poster Loft	Exhibition Hall
Time ▼						
08:00 – 09:00						
09:00 – 10:30	Resident and Fellow Education Program					
10:30 – 10:45	Coffee Break					
10:45 – 12:30	Resident and Fellow Education Program					
12:30 – 12:45						
12:45 – 13:30	¹ Corporate Lunch Session	Lunch Break				
13:30 – 14:00						
14:00 – 15:30	Plenary Session 1: Changing the Treatment Paradigm in Movement Disorders					
15:30 – 16:00	Coffee Break / Industry Exhibition					Meet Movement Disorder Fellowship Directors
16:00 – 17:30	Plenary Session 2: Target Specific and Disease Modifying Therapies					
17:30 – 17:45	Coffee Break / Industry Exhibition					
17:45 – 19:15	Opening Ceremony / IAPRD Lifetime Achievement Award / Melvin Yahr Lecture					

¹ 12:15 – 13:45 Acadia Pharmaceuticals Inc.

 Plenary Session	 Grand Parade Session	 Corporate Sessions (over Lunch)	 Resident and Trainee Program
 Parallel Track	 Coffee with the Professor	 Oral Poster Sessions	

	Resident and Fellow Education Program	Plenary Room W196
09:00 – 10:30	Resident and Fellow Education Program Chair: Hubert Fernandez (Cleveland, United States) Chair: Mark Lew (Los Angeles, United States)	
09:00 – 09:30	Talk 1: Epidemiology, etiology, and diagnosis of Parkinson disease Speaker: Caroline Tanner (San Francisco, United States)	
09:30 – 10:00	Talk 2: Treatment of motor symptoms of Parkinson disease with medications Speaker: Mark Lew (Los Angeles, United States)	
10:00 – 10:30	Talk 3: Treatment of motor symptoms of Parkinson disease with surgery Speaker: Joohi Jimenez-Shahed (New York City, United States)	
10:30 – 10:45	<i>Coffee Break</i>	
	Resident and Fellow Education Program	Plenary Room W196
10:45 – 12:30	Resident and Fellow Education Program Chair: Hubert Fernandez (Cleveland, United States) Chair: Mark Lew (Los Angeles, United States)	
10:45 – 11:15	Talk 4: Treatment of nonmotor symptoms of Parkinson disease Speaker: Deborah Hall (Chicago, United States)	
11:15 – 11:45	Talk 5: Tremor disorders Speaker: Pramod Pal (Bangalore, India)	
11:45 – 12:15	Talk 6: Hyperkinetic disorders Speaker: Hubert Fernandez (Cleveland, United States)	
12:15 – 12:30	Question and answer session Moderator: Hubert Fernandez (Cleveland, United States) Moderator: Mark Lew (Los Angeles, United States)	
12:30 – 14:00	<i>Lunch Break</i>	
	Plenary Session	Plenary Room W196
14:00 – 15:30	Plenary Session 1: Changing the Treatment Paradigm in Movement Disorders Chair: Cynthia Comella (Chicago, United States) Chair: Daniel Truong (Fountain Valley, United States)	
14:00 – 14:30	Plenary Session 1a: Parkinson disease Speaker: Stuart Isaacson (Boca Raton, United States)	
14:30 – 15:00	Plenary Session 1b: Tremor Speaker: William Ondo (Houston, United States)	
15:00 – 15:30	Plenary Session 1c: Dystonia Speaker: Cynthia Comella (Chicago, United States)	

SCIENTIFIC PROGRAM / SATURDAY, 13 MAY 2023

SATURDAY, 13 MAY 2023





		Meet Movement Disorder Fellowship Directors	Exhibition Hall
15:30 – 16:00		Meet Movement Disorder Fellowship Directors <i>Shilpa Chitnis (Dallas, United States)</i> <i>Marissa Dean (Birmingham, United States)</i> <i>Hubert Fernandez (Cleveland, United States)</i> <i>Karen Frei (Loma Linda, United States)</i> <i>Marie-Helene Saint-Hilaire (Boston, United States)</i>	
15:30 – 16:00		<i>Coffee Break / Industry Exhibition</i>	
		Plenary Session	Plenary Room W196
16:00 – 17:30		Plenary Session 2: Target Specific and Disease Modifying Therapies Chair: <i>Etienne Hirsch (Paris, France)</i> Chair: <i>Lorraine Kalia (Toronto, Canada)</i>	
16:00 – 16:30		Plenary Session 2a: Synucleinopathy and tauopathy Speaker: <i>Lorraine Kalia (Toronto, Canada)</i>	
16:30 – 17:00		Plenary Session 2b: Huntington Disease Speaker: <i>Cristina Sampaio (Princeton, United States)</i>	
17:00 – 17:30		Plenary Session 2c: Other Movement Disorders Speaker: <i>Ryuji Kaji (Tokushima, Japan)</i>	
17:30 – 17:45		<i>Coffee Break / Industry Exhibition</i>	
		Plenary Session	Plenary Room W196
17:45 – 19:10		Opening Ceremony / IAPRD Lifetime Achievement Award / Melvin Yahr Lecture Words of Welcome by the IAPRD President Speaker: <i>Daniel Truong (Fountain Valley, United States)</i> Words of Welcome by the Congress Chair Speaker: <i>Cynthia Comella (Chicago, United States)</i> IAPRD Lifetime Achievement Award – Stanley Fahn Speaker: <i>Serge Przedborski (New York City, United States)</i> IAPRD Melvin Yahr Award – Vincenzo Bonifati IAPRD 2023 Honorary Lecture: CSF1R-related leukoencephalopathy – from gene mutations discovery to therapies Speaker: <i>Zbigniew K. Wszolek (Jacksonville, United States)</i> <i>At the end of the Opening Ceremony all participants are invited to join the Welcome Reception in the exhibition area.</i>	

PROGRAM OVERVIEW / SUNDAY, 14 MAY 2023

SUNDAY, 14 MAY 2023

Room▶	Plenary Room W196	Room W194b	Room W192a	Room W192b	Poster Loft	Exhibition Hall
Time▼						
08:00 – 09:30	Plenary Session 3: Surgery in Movement Disorders: What's New?				Poster Exhibition	
09:30 – 10:30	Oral Presentations: Other Movement Disorders	Oral Presentations: PD: Clinical and Neuroscience	Coffee Break / Oral Presentations / Industry Exhibition	Oral Presentations: PD: Therapy		Coffee with the Professor
10:30 – 12:00	Parallel Session 1 (Clinical Practice Track): Workshops in Movement Disorders	Parallel Session 2 (Clinical Practice Track): Gait Disorders		Parallel Session 3 (Research/Translational Track): Recent Advances in Nonmotor Symptoms		
12:00 – 14:30	Lunch Break / Poster Exhibition / Industry Exhibition	¹ Corporate Lunch Session	² Corporate Lunch Session	³ Corporate Lunch Session		Lunch Break / Poster Exhibition / Industry Exhibition
				Lunch Break / Poster Exhibition / Industry Exhibition		
14:30 – 16:00	Plenary Session 4: Parkinson Disease Progression and Biomarkers					
16:00 – 16:30	Coffee Break / Poster Exhibition / Industry Exhibition					Coffee Break / Poster Exhibition / Industry Exhibition
16:30 – 18:00	Parallel Session 4 (Clinical Practice Track): Management of Resistant Parkinson Disease Symptoms	Parallel Session 5 (Education Track): Updates in Essential Tremor		Parallel Session 6 (Clinical Practice Track): Infectious and Autoimmune Movement Disorders		
18:00 – 18:30						
18:30 – 20:00	IAPRD Annual General Business Meeting					

- ¹ 12:15 – 13:45 Supernus
² 12:15 – 14:15 Merz Therapeutics
³ 12:15 – 13:45 Neurocrine

 Plenary Session	 Grand Parade Session	 Corporate Sessions (over Lunch)	 Resident and Trainee Program
 Parallel Track	 Coffee with the Professor	 Oral Poster Sessions	

	Plenary Session	Plenary Room W196
08:00 – 09:30	Plenary Session 3: Surgery in Movement Disorders: What's New? Chair: <i>Elena Moro (Grenoble, France)</i> Chair: <i>Leo Verhagen (Chicago, United States)</i>	
08:00 – 08:30	Plenary Session 3a: Use of focused ultrasound lesioning Speaker: <i>Jeff Elias (Charlottesville, United States)</i>	
08:30 – 09:00	Plenary Session 3b: Deep brain stimulation Speaker: <i>Elena Moro (Grenoble, France)</i>	
09:00 – 09:30	Plenary Session 3c: Cell based therapies Speaker: <i>Ryan Uitti (Jacksonville, United States)</i>	
09:30 – 10:30	<i>Coffee Break / Oral Presentations / Industry Exhibition</i>	
	Coffee with the Professor	Exhibition Hall
09:30 – 10:30	Coffee with the Professor Moderator: <i>Alberto Albanese (Milan, Italy)</i> Moderator: <i>Tanya Simuni (Chicago, United States)</i>	
	Oral Presentations	Plenary Room W196
09:30 – 10:30	Oral Presentations: Other Movement Disorders Chair: <i>Niccolo Mencacci (Chicago, United States)</i> Chair: <i>Genko Oyama (Tokyo, Japan)</i>	
09:30 – 09:40	Alterations of brain neurotransmitters and metabolites in a rat model of Huntington's disease Oral Presenter: <i>Ankush Kumar (New Delhi, India)</i>	
09:40 – 09:50	Perry syndrome (parkinsonism, neuropsychiatric symptoms, weight loss, hypoventilation): large new pedigree and first study on prodromal stage of the disease Oral Presenter: <i>Jaroslav Dulski (Jacksonville, United States)</i>	
09:50 – 10:00	Mutation screening of AOPEP variants in a large dystonia cohort Oral Presenter: <i>Junyu Lin (Chengdu, China)</i>	
10:00 – 10:10	Mitochondrial ATP synthase variants in dystonia, spastic paraplegia, and ataxia Oral Presenter: <i>Junyu Lin (Chengdu, China)</i>	
10:10 – 10:20	The Huntington Disease Health Index (HD-HI): Measuring changes in disease burden in response to valbenazine during the KINECT-HD-Trial Oral Presenter: <i>Chad Heatwole (Rochester, United States)</i>	
10:20 – 10:30	Fixing a shaky video to remotely program deep brain stimulation Oral Presenter: <i>Maria Belen Justich (Toronto, Canada)</i>	



Oral Presentations

Room W194b

09:30 – 10:30

Oral Presentations: PD: Clinical and Neuroscience

Chair: *Kailash Bhatia (London, United Kingdom)*

Chair: *Talene Yacoubian (Birmingham, United States)*

09:30 – 09:40

Representation of Parkinson's disease in the cinema

Oral Presenter: *Natalia Szejko (Calgary, Canada)*

09:50 – 10:00

The Parkinson's Disease-Health Index (PD-HI): development and validation of a novel, disease specific, patient reported outcome measure

Oral Presenter: *Jamison Seabury (Rochester, United States)*

10:00 – 10:10

Neurophysiological markers of motor reserve in Parkinson's disease

Oral Presenter: *Massimiliano Passaretti (Rome, Italy)*

10:10 – 10:20

Expanding the genetic basis of PD heterogeneity: Genome-Wide Association Study on PD subtypes

Oral Presenter: *Jaroslav Dulski (Jacksonville, United States)*



Oral Presentations

Room W192b

09:30 – 10:30

Oral Presentations: PD: Therapy

Chair: *Katerina Markopoulou (Chicago, United States)*

Chair: *Beom Seok Jeon (Seoul, South Korea)*

09:30 – 09:40

Connectivity profile for deep brain stimulation in early stage Parkinson disease

Oral Presenter: *David Charles (Nashville, United States)*

09:40 – 09:50

Image-guided programming in patients with Parkinson's disease with sub-optimal response to deep brain stimulation

Oral Presenter: *Viviana Torres (Barcelona, Spain)*

09:50 – 10:00

Geographic disparities and access to device-aided therapy services for medicare beneficiaries with advanced Parkinson's disease

Oral Presenter: *Hubert Fernandez (Cleveland, United States)*

10:00 – 10:10

Safety of Foslevodopa/Foscarbidopa during Optimization and Maintenance Treatment: Post Hoc Analysis of a Phase 3 Trial

Oral Presenter: *Pavnit Kukreja (Chicago, United States)*

10:10 – 10:20

Characterizing a Parkinson's Disease Population inadequately controlled by oral therapy: Baseline Characteristics of the Phase 3 Clinical Program for Foslevodopa/Foscarbidopa

Oral Presenter: *Pavnit Kukreja (Chicago, United States)*

10:20 – 10:30

Teleprogramming results in quicker optimization of DBS in Parkinson's disease: Early results from the ROAM-DBS trial

Oral Presenter: *Tucker Tomlinson (Plano, United States)*

**Parallel Session**

Plenary Room W196

10:30 – 12:00

Parallel Session 1 (Clinical Practice Track): Workshops in Movement DisordersChair: *Alberto Albanese (Milan, Italy)*Chair: *Joochi Jimenez-Shahed (New York City, United States)*

10:30 – 11:00

Parallel 1a: Use of botulinum toxin in movement disordersSpeaker: *Rupam Borgohain (Hyderabad, India)*

11:00 – 11:30

Parallel 1b: Workshop on DBS programmingSpeaker: *Benjamin Walter (Cleveland, United States)*

11:30 – 12:00

Parallel 1c: Workshop on pump technologiesSpeaker: *Angelo Antonini (Padua, Italy)***Parallel Session**

Room W194b

10:30 – 12:00

Parallel Session 2 (Clinical Practice Track): Gait DisordersChair: *Bas Bloem (Nijmegen, Netherlands)*Chair: *Philip Tipton (Jacksonville, United States)*

10:30 – 11:00

Parallel 2a: Gait in synucleinopathySpeaker: *Nicolaas Bohnen (Ann Arbor, United States)*

11:00 – 11:30

Parallel 2b: Gait in tauopathySpeaker: *Farwa Ali (Rochester, United States)*

11:30 – 12:00

Parallel 2c: Gait in normal pressure hydrocephalus (NPH) and other disordersSpeaker: *Philip Tipton (Jacksonville, United States)***Parallel Session**

Room W194b

10:30 – 12:00

Parallel Session 3 (Research/Translational Track): Recent Advances in Nonmotor SymptomsChair: *Dan Weintraub (Philadelphia, United States)*Chair: *Peter Hedera (Nashville, United States)*

10:30 – 11:00

Parallel 3a: DementiaSpeaker: *Melissa Jo Armstrong (Gainesville, United States)*

11:00 – 11:30

Parallel 3b: PsychosisSpeaker: *Dan Weintraub (Philadelphia, United States)*

11:30 – 12:00

Parallel 3c: AutonomicSpeaker: *Peter Hedera (Nashville, United States)*

12:00 – 14:30

Lunch Break / Poster Exhibition / Industry Exhibition

		Plenary Session	Plenary Room W196
14:30 – 16:00		Plenary Session 4: Parkinson Disease Progression and Biomarkers Chair: <i>Tanya Simuni (Chicago, United States)</i> Chair: <i>Un Kang (New York City, United States)</i>	
14:30 – 15:00		Plenary Session 4a: Challenges in measuring clinical disease progression in PD: Lessons from PPMI and clinical trials Speaker: <i>Tanya Simuni (Chicago, United States)</i>	
15:00 – 15:30		Plenary Session 4b: Neuroimaging biomarkers: SPECT vs MRI Speaker: <i>Jon Stoessl (Vancouver, Canada)</i>	
15:30 – 16:00		Plenary Session 4c: Other biomarkers (skin, CSF, blood, etc.) Speaker: <i>Yaroslau Compta (Barcelona, Spain)</i>	
16:00 – 16:30		<i>Coffee Break / Poster Exhibition / Industry Exhibition</i>	
		Parallel Session	Plenary Room W196
16:30 – 18:00		Parallel Session 4 (Clinical Practice Track): Management of Resistant Parkinson Disease Symptoms Chair: <i>Alberto Albanese (Milan, Italy)</i> Chair: <i>Bas Bloem (Nijmegen, Netherlands)</i>	
16:30 – 17:00		Parallel 4a: Sleep-wake disturbances Speaker: <i>Simon Lewis (Sydney, Australia)</i>	
17:00 – 17:30		Parallel 4b: Balance and falls Speaker: <i>Beom Seok Jeon (Seoul, Republic of Korea)</i>	
17:30 – 18:00		Parallel 4c: Diagnosis of speech and swallowing problems in PD Speaker: <i>Ailton Melo (Bahia, Brazil)</i>	
		Parallel Session	Room W194b
16:30 – 18:00		Parallel Session 5 (Education Track): Updates in Essential Tremor Chair: <i>Daniel Kremens (Philadelphia, United States)</i> Chair: <i>Joaquim Ferreira (Lisbon, Portugal)</i>	
16:30 – 17:00		Parallel 5a: Diagnosis Speaker: <i>Elan Louis (Dallas, United States)</i>	
17:00 – 17:30		Parallel 5b: Deep brain stimulation vs. focused ultrasound Speaker: <i>Raul Martinez-Fernandez (Madrid, Spain)</i>	
17:30 – 18:00		Parallel 5c: Drug treatment present and future Speaker: <i>Joaquim Ferreira (Lisbon, Portugal)</i>	

**Parallel Session****Room W192b**

16:30 – 18:00

Parallel Session 6 (Clinical Practice Track): Infectious and Autoimmune Movement DisordersChair: *Alfonso Fasano (Toronto, Canada)*Chair: *Jaroslav Sławek (Gdansk, Poland)*

16:30 – 17:00

Parallel Session 6a: COVID-19 and movement disordersSpeaker: *Alfonso Fasano (Toronto, Canada)*

17:00 – 17:30

Parallel Session 6b: Infectious movement disordersSpeaker: *Ai Huey Tan (Kuala Lumpur, Malaysia)*

17:30 – 18:00

Parallel Session 6c: Autoimmune movement disordersSpeaker: *Bettina Balint (Zurich, Switzerland)***Internal Sessions****Plenary Room W196**

18:30 – 20:00

IAPRD Annual General Business Meeting

PROGRAM OVERVIEW / MONDAY, 15 MAY 2023

MONDAY, 15 May 2023


Room ▶	Plenary Room W196	Room W194b	Room W192a	Room W192b	Poster Loft	Exhibition Hall
Time ▼						
08:00 – 09:30	Plenary Session 5: Genetics and Movement Disorders					
09:30 – 10:30	Coffee Break / Poster Exhibition / Industry Exhibition				Guided Poster Tours	Coffee with the Professor
10:30 – 12:00	Parallel Session 8 (Education Track): Career Enhancement Workshop	Parallel Session 7 (Clinical Practice Track): Video Workshop on Diagnostic Approach to Patients with Hyperkinetic Syndromes		Parallel Session 9 (Research/Translational Track): Update of Atypical Parkinsonian Syndromes	Poster Exhibition	
12:00 – 14:00	¹ Corporate Lunch Session	² Corporate Lunch Session		³ Corporate Lunch Session		Lunch Break / Poster Exhibition / Industry Exhibition
14:00 – 16:00	Plenary Session 6: Grand Parade of Movement Disorders Video Session					
16:00 – 16:15	Coffee Break / Poster Exhibition / Industry Exhibition					
16:15 – 17:45	Parallel Session 10 (Clinical Practice Track): Neurotoxins	Parallel Session 11 (Education Track): Skills Workshop in Deep Brain Stimulation		Parallel Session 12 (Clinical Practice Track): Drug-Related Movement Disorders		

¹ 12:15 – 13:45 Abbott


² 12:15 – 13:45 Merz Therapeutics

³ 12:15 – 13:15 AbbVie


 Plenary Session


 Grand Parade Session

 Corporate Sessions (over Lunch)

 Resident and Trainee Program

 Parallel Track

 Coffee with the Professor

 Oral Poster Sessions

	Plenary Session	Plenary Room W196
08:00 – 09:30	Plenary Session 5: Genetics and Movement Disorders Chair: Zbigniew K. Wszolek (Jacksonville, United States) Chair: Christine Klein (Lübeck, Germany)	
08:00 – 08:30	Plenary Session 5a: Parkinson disease genes and the role of routine clinical testing Speaker: Jaroslaw Dulski (Jacksonville, United States)	
08:30 – 09:00	Plenary Session 5b: Should genetic status influence treatment in Parkinson disease? Speaker: Andreas Puschmann (Lund, Sweden)	
09:00 – 09:30	Plenary Session 5c: Genetic testing in other movement disorders Speaker: Christine Klein (Lübeck, Germany)	
09:30 – 10:30	<i>Coffee Break / Poster Exhibition / Industry Exhibition</i>	
	Oral Presentations	Poster Loft
09:30 – 10:30	Guided Poster Tours Guided Poster Tour: PD: Therapy Moderator: Marie-Helene Saint-Hilaire (Boston, United States) Moderator: Leo Verhagen (Chicago, United States)	
P_48 (GPT)	Pallidal deep brain stimulation for Tourette's syndrome: a case series Oral Presenter: Prashant Natteru (Iowa City, United States)	
P_50 (GPT)	The location of subthalamic nucleus neurostimulation is associated with axial motor outcomes in Parkinson's disease Oral Presenter: Madison Butler (Ann Arbor, United States)	
P_52 (GPT)	Effectiveness of deep brain stimulation in Vietnamese patients with advanced Parkinson's disease Oral Presenter: Khang Chung Ngoc Vo (Ho Chi Minh, Vietnam)	
P_71 (GPT)	Current perspectives on the pharmacogenomics of the side effects of Parkinson's disease treatment: a systematic review Oral Presenter: Henry Mauricio Chaparro-Solano (Cleveland, United States)	
P_248 (GPT)	Pharyngeal structure and dysphagia in patients with parkinsonism Oral Presenter: Jeongeun Lee (Anyang, Republic of Korea)	
P_252 (GPT)	Combined physiotherapy and deep brain stimulation to improve independent community mobility in Parkinson's disease Oral Presenter: Rajasumi Rajalingam (Toronto, Canada)	

Guided Poster Tour: PD: Neuroscience

Moderator: *Etienne Hirsch (Paris, France)*

Moderator: *Serge Przedborski (New York City, United States)*

- P_07 (GPT) **Development and validation of the Vietnamese smell identification test (VSIT)**
Oral Presenter: *Thi Huyen Thuong Dang (Ho Chi Minh, Vietnam)*
- P_09 (GPT) **Role of brain renin angiotensin system in the pathophysiology of neurodegenerative disorders**
Oral Presenter: *Mohamed Abulfadl (Bristol, United Kingdom)*
- P_10 (GPT) **α -Synuclein induces neuroinflammation injury through the IL6ST-AS / STAT3/ HIF-1 α axis**
Oral Presenter: *Danyu Lin (Shenzhen, China)*
- P_12 (GPT) **Experimental model of parkinsonian diseases on the example of oxotremorine**
Oral Presenter: *Lobarkhon Alimbekova (Tashkent, Uzbekistan)*
- P_13 (GPT) **Estrogen and progesterone influence membrane functions and glucose transporter expression in synaptosomes of different age groups of naturally menopausal rats**
Oral Presenter: *Pardeep Kumar (Delhi, India)*
- P_36 (GPT) **pS129- α -Synuclein and α -synuclein in CNS-originating extracellular vesicles improve the differential diagnosis of Parkinson's disease and multiple system atrophy**
Oral Presenter: *Hash Brown Taha (Los Angeles, United States)*
- P_40 (GPT) **The Synuclein-One Study: Skin biopsy detection of phosphorylated alpha-synuclein for diagnosis of the synucleinopathies**
Oral Presenter: *Todd Levine (Scottsdale, United States)*
- P_74 (GPT) **Whole-exome sequencing study of Parkinson's disease in the Croatian population**
Oral Presenter: *Vladimira Vuletić (Rijeka, Croatia)*
- P_106 (GPT) **Serum inflammatory cytokines levels and the correlation analyses in Parkinson's disease**
Oral Presenter: *Sihui Chen (Chengdu, China)*

Guided Poster Tour: PD: Clinical



Moderator: *Anhar Hassan (Dublin, Ireland)*

Moderator: *Mark Lew (Los Angeles, United States)*

- P_64 (GPT) **Working memory dysfunctions in Parkinson's disease in a sample of the Tunisian population**
Oral Presenter: *Tarek Bellaj (Doha, Qatar)*
- P_79 (GPT) **Longitudinal analysis of plasma biomarkers for freezing of gait in Parkinson's disease**
Oral Presenter: *Ruwei Ou (Chengdu, China)*

- P_81 (GPT) **Observational study to investigate the relationship between stress related disorders and dysautonomic symptoms in Parkinson's disease**
Oral Presenter: *Daniel Martinez-Ramirez (Monterrey, Mexico)*
- P_96 (GPT) **A 26-week study of long-term adherence to a Iphone and Apple Watch based PROM platform: enhancing measurement and improving outcomes**
Oral Presenter: *Benoit Tas (Enghien, Belgium)*
- P_101 (GPT) **Feasibility of virtual measurement of sequential motor assessments for Parkinson's disease**
Oral Presenter: *Abdelwahab Elshourbagy (Cairo, Egypt)*
- P_105 (GPT) **Sex differences in the age at onset of Parkinson disease in Latin American populations**
Oral Presenter: *Janvi Ramchandra (Cleveland, United States)*
- P_150 (GPT) **Healthcare access in patients with Parkinson's disease – Analysis of the Health and Retirement Study**
Oral Presenter: *Natalia Szejko (Calgary, Canada)*
- P_157 (GPT) **Freezing of gait detection using RGB and walkway pressure data with AFSD algorithm**
Oral Presenter: *Kai-Cheng Hsu (Taichung, Taiwan)*
- P_158 (GPT) **Abnormalities on Pareidolia testing and visual hallucinations in patients with parkinsonism**
Oral Presenter: *Rupam Borgohain (Hyderabad, India)*
- Guided Poster Tour: Other Movement Disorders**
Moderator: *Karen Frei (Loma Linda, United States)*
Moderator: *Un Kang (New York City, United States)*
- P_25 (GPT) **Usefulness of Dual-Phase FP-CIT PET in distinguishing between corticobasal degeneration and idiopathic Parkinson disease within 2 years of disease duration**
Oral Presenter: *Min Seung Kim (Suwon, Republic of Korea)*
- P_177 (GPT) **Orthostatic hypotension in multiple system atrophy: related factors and disease prognosis**
Oral Presenter: *Qirui Jiang (Chengdu, China)*
- P_181 (GPT) **The perfusion of the parietal region as a feature of progressive supranuclear palsy subtypes**
Oral Presenter: *Natalia Madetko-Alster (Warsaw, Poland)*
- P_182 (GPT) **Remote assessments using wearable sensors can differentiate progressive supranuclear Palsy from Parkinson's disease**
Oral Presenter: *Anne-Marie Wills (Boston, United States)*
- P_205 (GPT) **Adult-onset tics after being crushed by an air conditioner – A case report**
Oral Presenter: *Madeline Kroeger (Iowa City, United States)*

- P_214 (GPT) **Another common genetic ataxia in South Korea: Spinocerebellar ataxia 36**
Oral Presenter: *Jinyoung Youn (Seoul, Republic of Korea)*
- P_237 (GPT) **Predictors of bone marrow transplant outcomes in CSF1R-related adult-onset leukoencephalopathy with axonal spheroids and pigmented glia**
Oral Presenter: *Jaroslav Dulski (Jacksonville, United States)*
- P_238 (GPT) **Differences in patient and healthcare professional perspectives on the key impacts of tardive dyskinesia**
Oral Presenter: *Stacy Finkbeiner (Parsippany, United States)*
- P_239 (GPT) **A novel C19ORF12 mutation in two MPAN sisters treated with deferiprone**
Oral Presenter: *Sihui Chen (Chengdu, China)*
- P_242 (GPT) **Real-world adherence to deutetrabenazine or valbenazine among patients with tardive dyskinesia**
Oral Presenter: *Stacy Finkbeiner (Parsippany, United States)*
- Guided Poster Tour: Resident and Trainee I**
Moderator: *Junaid Siddiqui (Cleveland, United States)*
Moderator: *Diego Torres-Russotto (Miami, United States)*
- P_68 (GPT) **Longitudinal cognitive changes in genetic and idiopathic Parkinson's disease: 5-year follow-up study**
Oral Presenter: *Olaia Lucas-Jiménez (Bilbao, Spain)*
- P_95 (GPT) **Evidence of intrinsic vestibular deficits in Parkinson's disease correlated with brain cholinergic system integrity**
Oral Presenter: *Simon David (Ann Arbor, United States)*
- P_103 (GPT) **Effect of changes in stomach and small intestinal pH on response to levodopa in patients with Parkinson's disease**
Oral Presenter: *Monica Arena (Portland, United States)*
- P_107 (GPT) **Touchscreen nQ application as a remote digital biomarker in Parkinson disease**
Oral Presenter: *Oliver Phillips (Cleveland, United States)*
- P_164 (GPT) **Association between lifestyle and environmental factors with disease severity and age at onset in multi-ethnic Malaysian Parkinson's disease patients**
Oral Presenter: *Jie Ping Schee (Kuala Lumpur, Malaysia)*
- P_165 (GPT) **Establishing a framework for quality of inpatient care for Parkinson's disease: a study on inpatient medication administration**
Oral Presenter: *Benjamin Walter (Cleveland, United States)*
- P_253 (GPT) **Effects of aerobic exercise on motor and non-motor symptoms of Parkinson's disease: a systematic review and meta-analysis**
Oral Presenter: *Muhammed Elfaituri (Tripoli, Libya)*

09:30 – 10:30	Guided Poster Tour: Resident and Trainee II Moderator: <i>Ruth Walker (New York City, United States)</i> Moderator: <i>Jinyoung Youn (Seoul, Republic of Korea)</i>
P_62 (GPT)	Exploration of antipsychotic prescribing practices among movement disorders subspecialists for patients Oral Presenter: <i>Karina Burda (Philadelphia, United States)</i>
P_194 (GPT)	Adult-onset cervical dystonia with botulinum toxin resistance and approach to severe spine deformity for deep brain stimulation: a case report Oral Presenter: <i>Emily Tamadonfar (Los Angeles, United States)</i>
P_201 (GPT)	New-onset Chorea post-SARS-CoV-2 infection: a case report Oral Presenter: <i>Benjamin Grimm (Iowa City, United States)</i>
P_204 (GPT)	Persistent chorea gravidarum with an autoimmune etiology: a follow up four years later Oral Presenter: <i>Shawn Sedgh (Loma Linda, United States)</i>
P_212 (GPT)	Translation and argentinean adaptation of the scale for the assessment and classification of Ataxia (SARA) Oral Presenter: <i>Julian Fernandez Boccazzi (Buenos Aires, Argentina)</i>
P_218 (GPT)	A case series of essential tremor featuring rest tremor of the lower extremities Oral Presenter: <i>Emily Tamadonfar (Los Angeles, United States)</i> Oral Presenter: <i>Janine Chan (Los Angeles, United States)</i>
	Coffee with the Professor Exhibition Hall
09:30 – 10:30	Coffee with the Professor Moderator: <i>Claire Henchcliffe (Irvine, United States)</i> Moderator: <i>Oksana Suchowersky (Alberta, Canada)</i>
	Parallel Session Plenary Room W196
10:30 – 12:00	Parallel Session 8 (Education Track): Career Enhancement Workshop Chair: <i>Un Kang (New York City, United States)</i> Chair: <i>Talene Yacoubian (Birmingham, United States)</i>
10:30 – 11:00	Parallel 8a: Conducting clinical trials Speaker: <i>Claire Henchcliffe (Irvine, United States)</i>
11:00 – 11:30	Parallel 8b: If I had to do it all over again Speaker: <i>Marie-Helene Saint-Hilaire (Boston, United States)</i> Speaker: <i>Fereshte Adib Saberi (Hamburg, Germany)</i> Speaker: <i>Ryan Utti (Jacksonville, United States)</i>
11:30 – 12:00	Parallel 8c: Setting up a multidisciplinary team Speaker: <i>Diego Torres-Russotto (Miami, United States)</i>



Parallel Session

Room W194b

10:30 – 12:00

Parallel Session 7 (Clinical Practice Track): Video Workshop on Diagnostic Approach to Patients with Hyperkinetic Syndromes

Chair: Pramod Pal (Bangalore, India)

Chair: Ruth Walker (New York City, United States)

10:30 – 11:00

Parallel 7a: Dystonias

Speaker: Sarah Pirio Richardson (Albuquerque, United States)

11:00 – 11:30

Parallel 7b: Ataxias

Speaker: Shinsuke Fujioka (Fukuoka, Japan)

11:30 – 12:00

Parallel 7c: Episodic and other rare movement disorders

Speaker: Anhar Hassan (Dublin, Ireland)



Parallel Session

Room W192b

10:30 – 12:00

Parallel Session 9 (Research/Translational Track): Update of Atypical Parkinsonian Syndromes

Chair: Horacio Kaufmann (New York City, United States)

Chair: Anne-Marie Wills (Boston, United States)

10:30 – 11:00

Parallel 9a: Multiple system atrophy

Speaker: Horacio Kaufmann (New York City, United States)

11:00 – 11:30

Parallel 9b: Progressive supranuclear palsy

Speaker: Irene Litvan (San Diego, United States)

11:30 – 12:00

Parallel 9c: Lewy body dementia

Speaker: John O'Brien (Cambridge, United Kingdom)

12:00 – 14:00

Lunch Break / Poster Exhibition / Industry Exhibition



Plenary Session

Plenary Room W196

14:00 – 16:00

Plenary Session 6: Grand Parade of Movement Disorders Video Session

Moderator: Mark Hallett (Bethesda, United States)

Chair: Bettina Balint (Zurich, Switzerland)

Chair: Kailash Bhatia (London, United Kingdom)

Chair: Ruth Walker (New York City, United States)

Video presenters:

Oday Halhouli (Iowa City, United States)

Arunmozhimaran Elavarasi (New Delhi, India)

Thien Thien Lim (Penang, Malaysia)

Ashley Durbin (Baltimore, United States)

Soaham Desai (Anand, India)

Ross Elizabeth Cortes (Cebu City, Philippines)

Kruzette Khloe Solijon (Cebu City, Philippines)

Surabhi Dharmadhikari (Chicago, United States)

Time for Questions and Answers will follow presentation of each video case.

**Parallel Session**

Plenary Room W196

16:15 – 17:45

Parallel Session 10 (Clinical Practice Track): Neurotoxins

Chair: Jarosław Sławek (Gdansk, Poland)

Chair: Dirk Dressler (Hannover, Germany)

16:15 – 16:45

Parallel 10a: Update on available botulinum neurotoxins

Speaker: Dirk Dressler (Hannover, Germany)

16:45 – 17:15

Parallel 10b: Novel and controversial indications for botulinum neurotoxins

Speaker: Raymond Rosales (Manila, Philippines)

17:15 – 17:45

Parallel 10c: Immuno-resistance to botulinum toxin: is it important?

Speaker: Hyder Jinnah (Atlanta, United States)

**Parallel Session**

Room W194b

16:15 – 17:45

Parallel Session 11 (Education Track): Skills Workshop in Deep Brain Stimulation

Chair: Daniel Martinez-Ramirez (Monterrey, Mexico)

Chair: Zoltan Mari (Las Vegas, United States)

16:15 – 16:45

Parallel 11a: Current hardware and adaptive stimulation

Speaker: Zoltan Mari (Las Vegas, United States)

16:45 – 17:15

Parallel 11b: New programming algorithms and teleprogramming

Speaker: Raja Mehanna (Houston, United States)

17:15 – 17:45

Parallel 11c: Non-PD and ET indications in movement disorders

Speaker: Philippe Salles-Gándara (Santiago, Chile)

**Parallel Session**

Room W192b

16:15 – 17:45

Parallel Session 12 (Clinical Practice Track): Drug-Related Movement Disorders

Chair: Karen Frei (Loma Linda, United States)

Chair: Joseph Friedman (Providence, United States)

16:15 – 16:45

Parallel 12a: Acute syndromes

Speaker: Joseph Friedman (Providence, United States)

16:45 – 17:15

Parallel 12b: Tardive syndromes

Speaker: Karen Frei (Loma Linda, United States)

17:15 – 17:45








Parallel 12c: Drug-induced parkinsonisms

Speaker: Daniel Kremens (Philadelphia, United States)

PROGRAM OVERVIEW / TUESDAY, 16 MAY 2023

TUESDAY, 16 May 2023

Room ▶	Plenary Room W196	Room W194b	Room W192a	Room W192b	Poster Loft	Exhibition Hall
Time ▼						
08:00 – 09:00	Plenary Session 7: The Current Symptomatic Treatment of Parkinson Disease: Lessons from the Latest Guidelines and Recommendations					
09:00 – 10:30	Special Plenary: Celebration of 30 Years of Deep Brain Stimulation					
10:30 – 11:30	Plenary Session 8: Device Interventions in the Treatment of Movement Disorders					
11:30 – 12:10	Best and Most Downloaded Papers in Parkinsonism and Related Disorders and Clinical Parkinsonism and Related Disorders Journals					
12:10 – 12:40	IAPRD 2022 Congress Awards and Closing Ceremony					

 Plenary Session	 Grand Parade Session	 Corporate Sessions (over Lunch)	 Resident and Trainee Program
 Parallel Track	 Coffee with the Professor	 Oral Poster Sessions	

	Plenary Session	Plenary Room W196
08:00 – 09:00	Plenary Session 7: The Current Symptomatic Treatment of Parkinson Disease: Lessons from the Latest Guidelines and Recommendations Chair: Robert Hauser (Tampa, United States) Chair: Teus van Laar (Groningen, Netherlands)	
08:00 – 08:30	Plenary 7a: Guidelines from the American Academy of Neurology Speaker: Janis Miyasaki (Alberta, Canada)	
08:30 – 09:00	Plenary 7b: Guidelines from the European Academy of Neurology / International Movement Disorder Society – European section Speaker: Angelo Antonini (Padua, Italy)	
	Plenary Session	Plenary Room W196
09:00 – 10:30	Special Plenary: Celebration of 30 Years of Deep Brain Stimulation Chair: Elena Moro (Grenoble, France) Chair: Leo Verhagen (Chicago, United States)	
09:00 – 09:20	Special Plenary a: History of deep brain stimulation Speaker: Elena Moro (Grenoble, France)	
09:20 – 09:40	Special Plenary b: Deep brain stimulation in the present Speaker: Joohi Jimenez-Shahed (New York City, United States)	
09:40 – 10:10	DBS 30-Year Celebration Break	
10:10 – 10:30	Special Plenary c: Future of deep brain stimulation Speaker: Ioannis Isaías (Würzburg, Germany)	
	Plenary Session	Plenary Room W196
10:30 – 11:30	Plenary Session 8: Device Interventions in the Treatment of Movement Disorders Chair: Diego Torres-Russotto (Miami, United States) Chair: Ioannis Isaías (Würzburg, Germany)	
10:30 – 11:00	Plenary 8a: Infusion therapies Speaker: Teus van Laar (Groningen, Netherlands)	
11:00 – 11:30	Plenary 8b: Ultrasound Speaker: Leo Verhagen (Chicago, United States)	
	Plenary Session	Plenary Room W196
11:30 – 12:10	Best and Most Downloaded Papers in Parkinsonism and Related Disorders and Clinical Parkinsonism and Related Disorders Journals Chair: Hubert Fernandez (Cleveland, United States) Chair: Huifang Shang (Chengdu, China)	
11:30 – 11:50	PRD Journal Speaker: Deborah Hall (Chicago, United States)	

11:50 – 12:10

CPRD Journal

Speaker: *Marie-Helene Saint-Hilaire (Boston, United States)*



Plenary Session

Plenary Room W196

12:10 – 12:40

IAPRD 2023 Congress Awards and Closing Ceremony

Chair: *Ron Pfeiffer (Portland, United States)*

Topic: Basic Neuroscience (excluding Genetics)

- P_01 **Role of heterozygous mutations in 'recessive' genes in Parkinson disease**
D. Azizova
- P_02 **Smek1 deficiency in PSP induces tau pathology via regulating Kif2a translocation**
R. Duan
- P_05 **Features of orthostatic hypotension in patients with mild cognitive impairment**
A. Ovchinnicova, Y. Trufanov
- P_07 (GPT) **Development and validation of the vietnamese smell identification test (vsit)**
T. H. T. Dang, T. H. Le, T. T. T. Nguyen, T. H. Nguyen, N. L. U. Ha, N. C. K. Vo, V. T. Nguyen, V. T. Nguyen, X. Q. Ly, T. T. Thai, N. T. Tran
- P_08 **The impact of altered sensory metacognition in Parkinson's disease**
A. Zaidel
- P_09 (GPT) **Role of brain renin Angiotensin system in the pathophysiology of neuro-degenerative disorders**
M. Abulfadl, S. Miners, R. Fisher, P. Kehoe
- P_10 (GPT) **α -synuclein induces neuroinflammation injury through the IL6ST-AS/STAT3/HIF-1 α axis**
D. Lin, K. Huang, E. Tao
- P_11 **Evaluation of orthostatic hypotension questionnaires**
A. Ovchynnykova, Y. Trufanov
- P_12 (GPT) **Experimental model of Parkinson's diseases on the example of oxotremorin**
L. Alimbekova, D. Tursunov
- P_13 (GPT) **Estrogen and progesterone influence membrane functions and glucose transporter expression in synaptosomes of different age groups of naturally menopausal rats**
P. Kumar, N. Baquer

Imaging and Biomarkers

- P_14 **Biochemical markers in Parkinson's disease**
M. Mirzayeva, D. Azizova
- P_15 **Biomarkers of vascular cognitive dysfunction. Identification of early markers of cognitive impairment before the development of dementia**
D. Azizova
- P_19 **The variability in clinical manifestations of brain iron deposition**
S. Jamall, K. Frei, E. Gray
- P_20 **Cerebrospinal fluid analysis in amyotrophic lateral sclerosis**
K. Klicova, J. Mareš, M. Kaiserova, K. Menšíková, D. Koničková, H. Šlanhořová, S. Cook, K. Langová, P. Kaňovský
- P_21 **Clinical improvement with normalization of dopamine transporter imaging in a patient with bupropion-induced parkinsonism**
X. Pizarro, P. Salles, P. Chana, F. Canals, M. Menares, V. Kramer
- P_22 **Pilot investigation of MRI-derived perfusion measures in cognitively impaired patients with Parkinson's disease**
B. Thomas, Z. Mari, V. Mishra
- P_23 **Hyperhomocysteinemia in Parkinson's disease.**
Z. Omonova, G. Rakhimbaeva, Y. Madjidova, Y. Musayeva

- P_25 (GPT) **Usefulness of Dual-Phase FP-CIT PET in distinguishing between corticobasal degeneration and idiopathic Parkinson's disease within 2 Years of disease duration**
M. S. Kim, D. G. Park, Y.-S. An, J. H. Yoon
- P_26 **The role of inflammation in the pathophysiology of primary tauopathies**
H. Šlanhofová, M. Nevrlý, K. Menšíková, D. Koníčková, K. Klíčová, S.E.V. Cook, J. Zatloukalová, P. Kaňovský
- P_27 **Characterization of the findings of the optical coherence tomography in patients with parkinson's disease**
O. Bernal, S. Poveda, X. Arellano, B. Quijano
- P_29 **MRI-based machine learning approach to predict the motor symptom severity in patients with Parkinson's disease**
A. Vijayakumari, H. Fernandez, B. Walter
- P_30 **Role of neuroinflammation on biomarker levels in the cerebrospinal fluid and blood serum of multiple system atrophy patients and controls**
S. Cook, P. Kaňovský, K. Menšíková, J. Zapletalová, D. Koníčková, H. Šlanhofová, K. Klíčová
- P_31 **The role of inflammatory biomarkers in the LBD neurodegenerative process**
D. Koníčková, K. Menšíková, K. Klíčová, H. Šlanhofová, S.E.V. Cook, J. Zapletalová, P. Kaňovský
- P_32 **Neurofilament light predicts weight loss in patients with Parkinson's disease: a prospective study**
K. Liu, R. Ou, Y. Hou, Y. Xiao, T. Yang, Q. Wei, J. Lin, W. Song, B. Zhao, X. Chen, Y. Wu, B. Cao, H. Shang
- P_34 **Longitudinal analysis of oligomeric alpha-synuclein in Parkinson's disease tears**
M. Lew, D. Feigenbaum, M. Tanveer, D. Gerke, B. Hjelm, W. Mack, M. Edman, S. Hamm-Alvarez
- P_35 **A proof of concept: digital diary using 24-hour monitoring using wearable device for patients with Parkinson's disease in nursing home**
H. Kamo, G. Oyama, Y. Yamazaki, T. Nagayama, R. Nawashiro, N. Hattori
- P_36 (GPT) **pS129- α -Synuclein and α -synuclein in CNS-originating extracellular vesicles improve the differential diagnosis of Parkinson's disease and multiple system atrophy**
H. B. Taha, S. Hornung, S. Dutta, L. Fenwick, O. Lahgui, K. Howe, N. Elabed, I. D. Rosario, D. Y. Wong, A. D. Folle, D. Markovic, J.-A. Palma, U. J. Kang, R. N. Alcalay, M. Sklerov, H. Kaufmann, B.L. Fogel, J.M. Bronstein, B. Ritz, G. Bitan
- P_38 **Correlates of cholinergic system vulnerability and resiliency in visual hallucinations in Lewy Body dementia**
I. Ghosh, R. Paalanen, S. Roytman, T. Brown, P. Kanel, N. Bohnen
- P_39 **Topography of cholinergic nerve terminal vulnerability and mobility self-efficacy in Parkinson's disease**
J. Barr, R. Paalanen, R. Vangel, S. Roytman, P. Kanel, N. Bohnen
- P_40 (GPT) **The Synuclein-One study: skin biopsy detection of phosphorylated alpha-synuclein for diagnosis of the synucleinopathies**
T. Levine, C. Gibbons, J. Stohl, B. Bellaire, R. Freeman
- P_41 **Topographic analysis of cerebral GABAA receptor availability and functional mobility in Parkinson's disease**
R. Vangel, R. Paalanen, J. Barr, S. Roytman, P. Kanel, N. Bohnen

Neurosurgery (including Deep Brain Stimulation)

- P_42 **Gait and speech improvement in one patient with 3-month adaptive STN-DBS therapy**
I.U. Isaías, L. Borellini, C. Palmisano, L. Caffi, V. Aglieri, F. Mameli, M. Arlotti, V. Aloia, F. Cogiamanian, S. Barbieri, A. Mazzoni, L. Rossi, G. Pezzoli, A. Priori, S. Marceglia, M. Locatelli
- P_43 **The added value of accelerometric monitoring during thalamotomy**
A. Smid, D.L.M. Oterdoom, R.W.J. Pauwels, K. Tamasi, J.W.J. Elting, A.R. Absalom, T. van Laar, J.M.C. van Dijk, G. Drost
- P_44 **Deep brain stimulation practices for Parkinson's disease in Chile**
P. Salles, C. Kunstman, A. De La Cerda, J.M. Tirapegui, X. Pizarro, D. Muñoz, M. Retamal, D. Aguirre, A. Fassler, C. Lazcano, C. Sepulveda, M.E. Contreras, M.C. Burgos, L. Acevedo, J.C. Nuñez, L. Hudson, P. Chana-Cuevas
- P_45 **Long-term outcome of globus pallidus interna deep brain stimulation for Parkinson's disease patients: five-year follow-up**
S.J. Chung, S. Jo, S.H. Lee, M.-S. Kim, S.R. Jeon, Y.S. Hwang
- P_46 **Autologous Unconditioned peripheral nerve tissue delivery to the substantia nigra (GUIDE) in patients with Parkinson's disease undergoing DBS surgery**
J. Hixson, J. Quintero, L. Ashe, Z. Ross, C. van Horne
- P_47 **Preliminary results from the Engage-PD study: enhancing gait using alternating-frequency DBS in Parkinson's disease**
J. Liao, R. Kaya, J. Yu, M. Koop, A. Rosenfeldt, J. Alberts, K. Baker, H. Fernandez
- P_48 (GPT) **Pallidal Deep Brain Stimulation for Tourette's syndrome: a Case Series**
P. Natteru, N. Narayanan, T. Thomsen
- P_49 **Right subthalamic nucleus active electrode location influences weight gain after deep brain stimulation**
A. Heston, A. Askari, K. Wyant, D. Leventhal, P. Patil, K. Chou
- P_50 (GPT) **The location of subthalamic nucleus neurostimulation is associated with axial motor outcomes in Parkinson's disease**
M. Butler, A. Askari, B. Zhu, K. Wyant, D. Leventhal, P.G. Patil, K.L. Chou
- P_51 **Acceptability of adaptive deep brain stimulation for Parkinson's Disease**
G. Oyama, A. Nakajima, Y. Shimo, H. Kamo, A. Umemura, H. Iwamuro, Y. Sekiguchi, A. Tsuchiya, T. Brionne, K. Noel, N. Hattori
- P_52 (GPT) **Effectiveness of deep brain stimulation in Vietnamese patients with advanced Parkinson's disease**
K. Chung Ngoc Vo, T. Huyen Thi Dang, U. Le Ngoc Ha, T. Thanh Thai, T. Ngoc Tran
- P_53 **Long-term safety of Magnetic resonance-guided high-intensity focused ultrasound in movement disorders: A systematic review and meta-analysis.**
A. Abusair, D. Abo Alsamh, N. Szejko, T.M. Pringsheim, D. Martino
- P_54 **Reconstructing time-domain data from discontinuous Percept™ output using external data acquisition and linear filtering**
J. Chen, K. Baker, J. Liao

Behavior, Cognition, Psychiatry

- P_55 **HIV associated Dementia, a clinical case report**
F. Yunusov
- P_56 **The impact of COVID-19 on depression in patients in Uzbekistan**
K. Narkulova, E. Shalaeva, A. Kostyunina, U. Bakhtiyorova

- P 59 **Clinical and neuropsychological characterization of patients with primary progressive aphasia in the DESCRIBE-FTD-study**
A. Mazrekaj, M. Wagner, A. Spottke, O. Peters, J. Priller, A. Hermann, I. Zerr, K. Buerger, G. Hoeglinger, J. Levin, S. Teipel, M. Synofzik, J. Prudlo, M. Brandt, J. Wiltfang, E. Duezel, M. Heneka, A. Schneider, P. Tacik
- P 60 **Distinctive course characteristics of depression and anxiety disorders in Parkinson's disease**
O. Naimov, R. Matmurodov, B. Muminov, K. Khalimova, R. Juraev, E. Abdukodirov
- P 61 **Some aspects of prediction dementia in patients with Parkinson's disease**
G. Rakhimbaeva, D. Okhunova
- P 62 (GPT) **Exploration of antipsychotic prescribing practices among Movement Disorders subspecialists for patients with Parkinson's Disease Dementia and Dementia with Lewy Bodies**
K. Burda, D. Selbst, J. Margolis, M. Heiry
- P 64 (GPT) **Working memory dysfunctions in Parkinson's disease in a sample of the Tunisian population**
T. Bellaj
- P 67 **Evaluation of voice intensity and speech loudness perception in Parkinson's Disease**
N. Janssen, F.P. Cárdenas, C. Calvache, Ó. Bernal-Pacheco, C. Cárdenas-Palacio
- P 68 (GPT) **Longitudinal cognitive changes in genetic and idiopathic Parkinson's disease: 5-year follow-up study**
O. Lucas-Jiménez, N. Ibarretxe-Bilbao, J. Peña, M. Acera, R. Del Pino, B. Tijero, J.C. Gómez-Esteban, I. Gabilondo, N. Ojeda

Parkinson Disease: Genetics

- P_71 (GPT) **Current perspectives on the pharmacogenomics of the side effects of Parkinson's disease treatment: a systematic review**
H.M. Chaparro-Solano, M. Rivera Paz, J. Hockings, H.H. Fernandez, I.F. Mata
- P_72 **Factors predicting amantadine response among patients with Parkinson's-disease.**
L. Saadatpour, J.R.T. Yu, H. Kaur, I. Mata, H.H. Fernandez
- P_74 (GPT) **Whole-exome sequencing study of Parkinson's Disease in the Croatian population**
V. Racki, E. Papic, M. Hero, G. Rozmaric, A. Kovanda, A. Maver, G. Bergant, N. Starcevic Cizmarevic, B. Peterlin, V. Vuletic
- P_76 **A study of genetic variation associated with rates of motor and nonmotor progression in early Parkinson's disease**
J. Iyer, E. Macklin, T. Simuni, M. Schwarzschild, G. Crotty
- P_77 **Parkinson's Disease Genetic results from a large Midwest cohort: the Gary A Smith PD GENERation Site**
A. Richmond, K. Lyons, R. Pahwa

Parkinson Disease: Subtypes, natural course

- P_78 **Relationship between peripheral adaptive immune markers and Parkinson's disease progression**
X. Yi, Q. Wei, R. Ou, T. Yang, Q. Jiang, Y. Hou, L. Zhang, K. Liu, S. Wang, J. Lin, B. Zhao, W. Song, X. Chen, Y. Wu, C. Li, H. Shang

- P_79 (GPT) **Longitudinal analysis of plasma biomarkers for freezing of gait in Parkinson's disease**
R. Ou, Y. Hou, J. Lin, K. Liu, T. Yang, Y. Xiao, Q. Wei, C. Li, L. Zhang, Z. Jiang, B. Zhao, X. Chen, W. Song, Y. Wu, H. Shang
- P_81 (GPT) **Observational study to investigate the relationship between stress related disorders and dysautonomic symptoms in Parkinson's Disease**
E. J. Acosta Espinoza, I. A. Ortiz Marroquin, D. I. Salinas Leal, A. Salinas Blancas, H. M. Macias Cruz, D. Martinez-Ramirez
- P_82 **The impact of type 2 diabetes mellitus drugs on the onset of Parkinson's disease**
G. Pezzoli, E. Cereda, P. Amami, S. Colosimo, M. Barichella, C. Klersy, R. Cilia, I.U. Isaias
- P_83 **Relationship between Postural instability and Gait Difficulties, Visuo-cognition, and Vision in Parkinson's disease**
M. van Emde Boas, C. Pongmala, A. Griggs, A. Biddix, J. Caswell, P. Kanel, N.I Bohnen
- P_84 **Postural Control Subtypes in Parkinson's Disease and Older Adults**
S. Roytman, R. Paalanen, H. Bhandari, J. Barr, R. Vangel, P. Kanel, N. Bohnen

Parkinson Disease: Clinical assessment (including devices)

- P_85 **Evaluation of the clinical outcomes and Disease Burden in Advanced Parkinson's Disease Patients: PROSPECT Study Preliminary Results**
A.J. Espay, P.S. Alonso, D. Falconer, C. Ferguson, K. Hasegawa, M. Rollins Hatcher, P. Kukreja, K. Onuk, C.H. Yan, J. Zamudio, V.S. Fung
- P_86 **Technology for virtual assessment of the quality of rhythmic movements in the extremities**
J. Brasic, A. Elshourbagy, M. Eltaras, H. Abdalshafy, S. Javed, T. Harrigan, K. Mills, M. Hernandez
- P_87 **Community-Academic Initiative to Measure and Improve Underrepresented Group Participation in Parkinson's Disease Research**
A. Marre, E. Zivin, K. Williams, M. Shramuk, N. Lancki, J. Adrissi, D. Larson
- P_89 **Wearables for Advanced Parkinson's Therapy Screening and Management**
R. Fadil, G. Kuhlman, B. Walter, D. Heldman
- P_90 **Actigraphy shows feasibility as a biomarker of dopaminergic medication use and motor fluctuations in Parkinson's disease**
J.H. Chang, D. Bhatti, E. Uc, M. Rizzo, J. Merickel
- P_91 **Is there a white coat effect in Parkinson disease?**
O. Phillips, A. Amato, H.H. Fernandez
- P_93 **Clinical and motor fluctuation assessment with a mobile app and electronic diary**
C. Cerquera-Cleves, A. Ferreirós
- P_95 (GPT) **Evidence of intrinsic vestibular deficits in Parkinson's disease correlated with brain cholinergic system integrity**
S. David, S. Roytman, D. McCaslin, P. Kanel, C. Pongmala, A. Griggs, T. Brown, K. Kerber, N. Bohnen
- P_96 (GPT) **A 26-week study of long-term adherence to a Iphone and Apple Watch based PROM platform: enhancing measurement and improving outcomes**
B. Tas, B. Duvivier, H. Mueller, J.M. Dean, C. van der Linden

- P_97 **Emotional valence of olfactory identification in UPSIT predicts motor progression in Parkinson's disease**
Y.-H. Lin, T.-C. Fang, H.-B. Lei, S.-C. Chiu, Y.-J. Guo
- P_99 **Acceptability of movement-prompting rehabilitation device to increase non-exercise physical activity levels in people with Parkinson's disease**
A. Biddix, C. Pongmala, F. Michalakakis, M. van Emde Boas, J. Richardson, N. Bohnen
- P_100 **Composite measures of motor performance and self-efficacy are better determinants of postural instability and gait difficulties than individual clinical measures in Parkinson's disease**
C. Pongmala, M. van Emde Boas, A. Griggs, S. Roytman, A. Biddix, P. Kanel, R.L. Albin, N.I. Bohnen
- P_101 (GPT) **Feasibility of virtual measurement of sequential motor assessments for Parkinson's disease**
A. Elshourbagy, M.M. Eltaras, H. Abdalshafy, A. O. Sadaney, T. P. Harrigan, Alexander Mills, M. Enrique Hernandez, J.R. Basic
- P_102 **The Effect of 4-month Exercise Programme on Timed Up and Go Test in Patients with Parkinsons Disease – interim analysis**
P. Martiš, I. Straka, Z. Urbančík, L. Slobodová, V. Litvákova, J. Ukropec, B. Ukropcová, P. Valkovič, Z. Košutzká
- P_103 (GPT) **Effect of changes in stomach and small intestinal pH on response to levodopa in patients with Parkinson's Disease.**
M. Arena, R. Pfeiffer, D. Safarpour
- P_104 **Impact of covid-19 infection on the course of parkinson's disease**
B. Muminov, R. Matmurodov, R. Juraev, K. Khalimova
- P_105 (GPT) **Sex Differences in the Age at Onset of Parkinson's Disease in Latin American Populations**
J. Ramchandra, H. M. Chaparro-Solano, M. Inca-Martinez, T.P. Leal, E. Gatto, F. Micheli, B.L. Santos-Lobato, A. F. Schumacher-Schuh, C. R. de Mello Rieder, V. Tumas, B. Vanderci, P. Chana, P. Olguin, G. Arboleda Bustos, J.L. Orozco Vélez, C. Velez-Pardo, G. Torrealba-Acosta, A. Medina, M. Rodriguez-Violante, D. Martinez-Ramirez, I. Estrada-Bellmann, M. Cornejo-Olivas, A.C. Medina Colque, A. Viñuela, E. Dieguez, V. Raggio, I.F. Mata, on behalf of the Latin American Research Consortium on the Genetics of PD (LARGE-PD)
- P_106 (GPT) **Serum inflammatory cytokines levels and the correlation analyses in Parkinson's disease**
S. Chen, J. Fu, J. Liu, J. Yang, R. Ou, L. Zhang, X. Chen, H. Shang
- P_107 (GPT) **Touchscreen nQ application as a remote digital biomarker in Parkinson disease**
O. Phillips, J.R.T. Yu, P. Salles, J. Kosco, J. Cook, C. Cannon, A.A. Holmes, I. Mondesire-Crump, J. Syrotenko, S. Mruthik, T. Arroyo-Gallego, H.H. Fernandez
- P_109 **Visualization of the MDS-UPDRS results**
J. Hixson, J. Quintero, A. Guiliani, T. Yamasaki, G. Gerhardt, J. Slevin, C. van Horne
- P_110 **Smartphone app-based tapping test characteristics in a longitudinal cohort of Parkinson's disease patients**
J. Abanto, K. Duque, A. Mahajan, M. Bologna, A.J. Espay, L. Marsili
- P_111 **Levodopa-entacapone-carbidopa intestinal gel (LECIG) for advanced Parkinson's – single centre experience from Romania**
J. Szász, V. Constantin, M. Ciorba, S. Bătagă
- P_112 **Clinical and sensor-based motor outcome parameters as predictors of freezing of gait in Parkinson's disease**
C. Pongmala, A. Griggs, M. van Emde Boas, R.L. Albin, N.I. Bohnen

P_114 **Quantitative analysis of static postural balance between faller and non-faller in patients with Parkinson's disease**
D.-Y. Kwon

P_115 **Change of Gait in Parkinson's Disease Patients According to Electrode Localisation in Subthalamic Nucleus**
M. Nevrlý, J. Bardoň, D. Burd'áková, J. Valošek, D. Krahulík, P. Otruba, B. Kolářová, P. Kaňovský

Parkinson Disease: Therapy (excluding surgical, physical)

P_116 **Enrollment characteristics for patients entering a Phase 3 study of subcutaneous levodopa/carbidopa infusion with ND0612**
J. Ferreira, O. Rascol, A. Albanese, A. Ellenbogen, N. Giladi, T. Gurevich, S. Hassin-Baer, J. Hernandez-Vara, S. Isaacson, K. Kieburtz, P. LeWitt, L. Lopez Manzanara, C.W. Olanow, R. Pahwa, W. Poewe, H. Sarva, F. Stocchi, T. Yardeni, L. Adar, L. Salin, N. Lopes, N. Sasson, R. Case, A. Espay

P_117 **Rationale for a potentially pivotal study of NE3107 in Parkinson's disease**
N. Osman, C. Ahlem, C. Reading, J. Djan, J. Palumbo

P_118 **Rapid onset of good ON time and improvement in motor-state stability in aPD patients after treatment with continuous subcutaneous foslevodopa/foscarbidopa**
R. Pahwa, M.J. Soileau, D.G. Standaert, V.S. Fung, T. Kimber, I. Malaty, A. Merola, A.J. Epstein, C.H. Yan, A. Alobaidi, A. Shewale, N. Fisseha, A. Jeong, M.F. Facheris, P. Kukreja, J. Zamudio, J. Aldred

P_119 **Use of Glutathione in Parkinson's disease at earlier stages of the disease and the prognosis of delaying its progression**
S. Musayev, G. Rakhimbaeva, Y. Madjidova, Y. Musayeva

P_120 **Impact of physical activity to expand serum a klotho levels amidst people with Parkinson disease**
W. Moses, N. Jennifer, K. Mugabi, N. Lukia

P_121 **The Phase 2, randomized, placebo-controlled PRECEDENT trial of SAGE-718 in patients with Parkinson's disease cognitive impairment: clinical trial in progress**
A. Bullock, A. Koenig, K. Paumier, J. Wald, S. Park, M. Quirk, J. Petrillo, J. Doherty

P_122 **Protocol to Help Neurologists Manage Subcutaneous Apomorphine Therapy Skin Nodules: Expert Roundtable Recommendations**
S.H Isaacson, M.S Grall, F. Gupta, D. Kremens, C. Nguyen, R. Pahwa, M. Serota, M. Zirwas, S. Feldman

P_123 **Targeting the gut-brain axis in Parkinson's disease: preliminary findings from butyric acid supplementation in Parkinson's Disease**
A. Griggs, S. Roytman, R. Vangel, J. Bohnen, J. Barr, R. Albin, N. Bohnen

P_125 **Dysphagia and mortality in people with parkinson's disease treated with levodopa-carbidopa intestinal gel**
D. Rinaldi, G. Imbalzano, F. Pontieri, L. Lopiano, S. Galli, E. Bianchini, C.A. Artusi

P_126 **Subgroup analyses of effect of treatment with Levodopa Inhalation Powder (CVT-301) 84 mg by Severity of OFF Symptoms in People With Parkinson's Disease, as Assessed by the Unified Parkinson's Disease Rating Scale Part III (UPDRS-III)**
R. Cohen, P. Zhao, R. Marini, B. Blank, D. Grosset

P_127 **A Population Pharmacokinetic Comparison of Three Amantadine Formulations**
Z. Wang, R. Gomeni, R. Hauser, R. Pahwa, O. Rascol, A. Gebre, G. Ceresoli-Borroni

- P_128 **Predictability of GOOD ON time during the waking day with amantadine extended-release capsules: A post-hoc analysis of pooled pivotal trials**
R. A. Hauser, A. E. Formella, P. Qin, M.S. Grall
- P_130 **L-dopa with entacapone as a rescue therapy after a failed attempt to start Duodopa - a case report**
M. Switonska
- P_132 **Real-World Utilization of Istradefylline among Patients with Parkinson's Disease**
M. Rezak, J. Qian, Y. Zhao, A.R. Silverstein, J. Chambers, J. Swindle, N. Kronfeld, P. LeWitt
- P_133 **Apomorphine hydrochloride injection (Apokyn®) treatment initiations in the presence and absence of an antiemetic in people with Parkinson disease**
C. Happel, M. Grall, A. Formella
- P_134 **Non-invasive Transcutaneous Afferent Patterned Stimulation Therapy Offers Action Tremor Relief in Parkinson's Disease**
S. Isaacson, S. Brillman, P. Khemani, R. Pahwa, R. Deshpande, V. Zraick, K. Rosenbluth, D. Khosla
- P_135 **Optimizing Augmented Reality Cueing Strategies for Freezing of Gait in Parkinson Disease: The ELIMINATE FoG Study**
B. Baugher, R. Kaya, K. Scelina, D. Ghosh, A. Amato, K. Baker, H.H. Fernandez, J. Alberts, N. Szewczyk, J. Liao
- P_136 **Quality of life with continuous subcutaneous levodopa/carbidopa infusion: Exploratory findings from the ND0612 BeyoND study**
S. Isaacson, W. Poewe, R. Case, L. Adar, T. Yardeni, A. Espay
- P_137 **Impact of the highly selective D1/D5 partial dopamine agonist tavapadon on daytime sleepiness: evidence from a phase 2 clinical trial**
M. Leoni, I. Chang, C. Combs, A. Gangadharan, G. Pastino, S. Duvvuri
- P_138 **Continuous, Subcutaneous Apomorphine Infusion for Persistent Motor Fluctuations in Parkinson's Disease: Full results of the AP2-3000 open-label study**
S. Isaacson, G. Ceresoli-Borroni, A. Espay, R. Pahwa, P. Agarwal, H. Shill, J. Hui, K. Dashtipour, M. Lew, P. Qin, A. Nasser, P. LeWitt
- P_139 **The complexity of Parkinson disease medication regimens may factor into treatment decisions: Results of a PMD Alliance survey**
N. Crouse, J. Farmer, C.J. Goas, J. Rivera, A. Mitchell, A. Merriam, A. Formella
- P_140 **A blind computerized analysis. Effect of subthalamic deep brain stimulation on posture in Parkinson Disease**
F. Rakhimov, G. Sattarovna

Parkinson Disease: Other topics

- P_141 **The importance of drug therapy and deep brain stimulation (DBS) in the treatment of Parkinson's disease**
D. Khakimova, D. Azizova
- P_142 **Parkinson disease psychosis: a case report**
S. Zmantar, A. Mhalla, L. Gaha
- P_144 **Psycho-emotional disorders in Parkinson's disease**
D. Khakimova, D. Akramova
- P_145 **Kampavata AKA Parkinson's disease in Ayurveda, it's etiology and therapy**
S. Rajpoot, N. Khatri

- P_148 **Novel characteristics of the temporal transition to maximum tongue pressure in Parkinson's disease: A pilot study**
S. Hayasaka, K. Hatori
- P_150 (GPT) **Healthcare Access in Patients with Parkinson's disease – Analysis of the Health and Retirement Study**
N. Szejko, A. Dunalska, K. Saramak, V. Carvalho, A. Abusair
- P_152 **Risk disclosure in prodromal Parkinson's disease – A survey of neurologists**
G. Kayis, R. Yilmaz, B. Arda, M.C. Akbostanci
- P_153 **The diagnosis value of dopaminergic responsiveness of Parkinson's disease: a systematic review and meta-analysis**
H. Cai, W. Kou, T. Feng
- P_154 **Pharmacokinetic differences of caffeine between lrrk2 g2019s knock-in and wild-type mice**
S. Ayer, C.N. Hoang Kieu, S. Lin, M. Sotolongo-Serret, S. Ubiera Rodriguez, R. Bakshi, M. Schwarzschild
- P_156 **The prevalence of Restless legs syndrome in Parkinson's disease in Colombia**
J.D. Vargas Jaramillo
- P_157 (GPT) **Freezing of Gait Detection Using RGB and Walkway Pressure Data with AFSD Algorithm**
K.-C. Hsu
- P_158 (GPT) **Abnormalities on Pareidolia testing and visual hallucinations in patients with Parkinsonism**
R. M. Kandadai, M. Cherukuri, S. S. Meka, R. Alugolu, R. Borgohain
- P_159 **Investigating Factors Contributing to Clinical Trial Recruitment in Parkinson's Disease within the Black Community**
J. Adrissi, C. Onwumere, D. Dominguez, M. Lyleroehr, E. Gray, K. Williams, E. Zivin, D. Larson
- P_162 **Social and gender inequity on overall survival and access to deep brain stimulation in Parkinson disease patients in Colombia**
C. Pantoja-Ruiz, D. Rosselli
- P_164 (GPT) **Association between Lifestyle and Environmental Factors with Disease Severity and Age at Onset in multi-ethnic Malaysian Parkinson's Disease Patients**
J. P. Schee, H. C. Ting, Z. L. Loo, C. Y. Lew, A. M. F. Dy Closas, T. S. Toh, J. W. Hor, Y. W. Tay, J. L. Lim, L. Y. Tan, L. C. Lit, A. H. Tan, S.-Y. Lim
- P_165 (GPT) **Establishing a framework for quality of inpatient care for Parkinson's disease: a study on inpatient medication administration**
B. Walter, J. R. T. Yu, C. Sonneborn, O. Hogue, D. Ghosh, A. Brooks, J. Liao, H. Fernandez, S. Shaffer, S. Sperling
- P_166 **Relationship between visuo-motor Stroop stepping task reaction time and regional cholinergic denervation in Parkinson Disease**
J. Caswell, S. Roytman, J. Barr, I. Ghosh, R. Albin, P. Kanel, N. Bohnen
- P_167 **Effect of amyloid on cognitive performance in Parkinson's disease and dementia with Lewy bodies**
K. Baik, M. Park, H.K. Na, Y.H. Sohn, P.H. Lee

Other Parkinsonian Disorders

- P_169 **Hydrocephalus Associated With Chiari-I Malformation Presenting with Parkinsonism And Dystonia**
A. Maheshwary, L. Wolansky, B. Rodrigues, K. Bulsara, D. Karimeddini, B. Sprin-gate, N. Prakash

- P_170 **Comparative analysis of the occurrence of nonmotor disorders in Parkinson's disease and vascular parkinsonism**
R. Juraev, R. Matmurodov, B. Muminov, K. Khalimova, O. Naimov, E. Abdukodirov
- P_171 **Exposure to Lambda-cyhalothrin induces motor dysfunctions and impairs striatal REDOX homeostasis and β -arrestin-dependent Akt signaling in adult Wistar rats**
A. Kumari, A. Srivastava, V. Khanna
- P_172 **Failure to predict outcomes of ventriculoperitoneal shunting in normal pressure hydrocephalus patients using multi-variable logistic regression models**
A. Kundrick, B. Baugher, J. Liao, C. Sonneborn, O. Hogue, D. Ghosh, P. Gilson, C. Fellows, P. Salles Gandara, H. Fernandez, S. Nagel
- P_173 **External lumbar drain trial walk tests as predictors of ambulatory Clinical Global Impression rating after ventriculoperitoneal shunting in NPH**
B. Baugher, A. Kundrick, J. Liao, P. Salles Gandara, H. Kaur, C. Fellows, D. Ghosh, P. Gilson, H.H. Fernandez, S. Nagel
- P_174 **Topography of differential cholinergic vulnerability in Parkinson's Disease and atypical parkinsonisms: A [18F]-FEOBV PET study**
P. Kanel, S. Roytman, J. Barr, T. Brown, N.I. Bohnen
- P_176 **Parkinsonism secondary to mercury poisoning in a Colombian population.**
J.D. Vargas Jaramillo
- P_177 (GPT) **Orthostatic hypotension in multiple system atrophy: related factors and disease prognosis**
Q. Jiang, L. Zhang, J. Lin, Q. Wei, C. Li, Y. Hou, R. Ou, K. Liu, T. Yang, Y. Xiao, B. Zhao, Y. Wu, H. Shang
- P_180 **Striatal encephalitis: a cause of rapid onset parkinsonism**
A. Toth, H. Abboud
- P_181 (GPT) **The perfusion of the parietal region as a feature of Progressive Supranuclear Palsy subtypes**
P. Alster, N. Madetko-Alster, B. Migda, L. Królicki, A. Friedman
- P_182 (GPT) **Remote assessments using wearable sensors can differentiate Progressive Supranuclear Palsy from Parkinson's Disease**
A.-M. Wills, R. Mishra, M. Sharma, A.J Hall, J. Casado, R. Cole, A. Vaziri, A. Pante-lyat
- P_184 **Automatic stridor detection using small training set via patch-wise few-shot learning for diagnosis of multiple system atrophy**
J.H. Ahn, J. Ha, J.H. Lee, C.Y. Lim, E.Y. Joo, J. Youn, M.J. Chung, J.W. Cho, K. Kim
- P_185 **Diagnostic utility of movement disorder society criteria for multiple system atrophy**
L. Zhang, Y. Hou, Q. Wei, R. Ou, K. Liu, J. Lin, T. Yang, Y. Xiao, B. Zhao, H. Shang
- P_186 **Idiopathic normal pressure hydrocephalus features on MRI in patients with pathologically confirmed progressive supranuclear palsy**
M. Kawazoe, S. Koga, H. Sekiya, N. Graff-Radford, D.W. Dickson

Dystonia

- P_188 **Initial experience in Bolivia with HU-014 (a non-FDA-approved botulinum toxin A) for Movement Disorders.**
M.R. Jauregui Villar, P. Chaná-Cuevas, P. Salles Gándara
- P_189 **Hemidystonia-hemiatrophy syndrome: first case report in bolivia**
S. Silva

- P_190 **A Novel THAP1 Variant Presenting with Early Onset Generalized Dystonia**
A.M. Dellert, B. Rodrigues, N. Prakash
- P_191 **Cacna1a variant can be associated with generalized dystonia**
D. Rinaldi, G. Imbalzano, C.A. Artusi
- P_192 **Distal lower extremity task specific dystonia symptoms in runners**
M. Moreno-Escobar, R. Thompson, D. Torres-Russotto, A. Hellman
- P_193 **Oromandibular dystonia as a cause of temporomandibular joint degeneration: case report**
C. Anunciação, J. Melo, B. Rodrigues, L. Lins-Kusterer, A. Melo
- P_194 (GPT) **Adult-Onset Cervical Dystonia with Botulinum Toxin Resistance and Approach to Severe Spine Deformity for Deep Brain Stimulation: A Case Report**
E. Tamadonfar, B. Lee, J. Liu, M. Lew
- P_195 **Oculogyric crisis as a result of dopamine blocking agent withdrawal**
L. Saadatpour, J. Liao
- P_196 **Benefit of multiple incobotulinumtoxinA injections for pain reduction in adults with cervical dystonia: an analysis of pooled data**
A. Albanese, J. Wissel, W. Jost, A. Castagna, M. Althaus, G. Comes, A. Scheschonka, M. Vacchelli, H. Jinnah
- P_197 **Pain reduction in adults with cervical dystonia following a single injection of incobotulinumtoxinA: a pooled analysis**
A. Albanese, J. Wissel, W. Jost, A. Castagna, M. Althaus, G. Comes, A. Scheschonka, M. Vacchelli, H. Jinnah

Chorea, Athetosis, Ballism, Tics

- P_198 **Extrapyramidal and movement disorder, unspecified**
U. Abdullazizova
- P_200 **Post-pump hemichorea in an adult: a case report**
R. Lee, E. Jackowiak
- P_201 (GPT) **New-onset Chorea post-SARS-CoV-2 infection: a case report**
B. Grimm, P. Natteru, C. Groth
- P_202 **Late-onset chorea-dystonia related to a novel ADCY5 variant**
X. Pizarro, P. Salles, P. Saffie, F. Canals, P. Chana, J.M. Tirapegui
- P_203 **A paradoxical phenomenon: Hemichorea-hemiballismus resolution after stroke in Moya-moya disease**
C. Y. Por, T.T. Lim, Y.C. Chee, R. Azman Ali
- P_204 (GPT) **Persistent Chorea Gravidarum with an Autoimmune Etiology: a Follow Up Four Years Later**
S. Sedgh, C. Kamen, K. Frei
- P_205 (GPT) **Adult-onset tics after being crushed by an air conditioner – A case report**
M. Kroeger, P. Natteru, T. Thomsen
- P_206 **Crushing valbenazine capsule contents for potential addition to soft foods or administration via G-tube**
S. Hinton, M. Hebert, A. Mar, R. Moore, A. Bristow, S. Siegert
- P_207 **A paradoxical phenomenon: Hemichorea-hemiballismus resolution after stroke in Moya-moya disease**
C. Y. Por, T.T. Lim, Y.C. Chee, A.A. Raymond

P_209 **Indirect Treatment Comparison of Valbenazine with Deutetrabenazine for Improvement in Total Maximal Chorea Score in Huntington Disease**

R. Mehanna, E. Furr Stimming, D. Haubenberger, O. Klepitskaya, S. Aggarwal, S. Kumar, O. Topaloglu, J. Goldstein, E. Kayson, M. Serbin

P_210 **Once-Weekly Robotic-Assisted Gait Training Preserves Walking Function in Hereditary Spastic Paraplegia: a Case Report**

R. Hand

Ataxias, hereditary spastic paraparesis

P_211 **Short-term efficacy of repetitive transcranial magnetic stimulation in SCA3: a prospective, randomized, double-blind, sham-controlled study**

H.-L. Xu, A. Sikandar, X.-H. Liu, S.-R. Gan

P_212 (GPT) **Translation and argentinean adaptation of the Scale for the Assessment and Classification of Ataxia (SARA)**

J. Fernandez Boccazzj, B. Eizaguirre, X. Merchan del Hierro, J.L. Etcheverry, N. González Rojas, V. Aldinio, G. Persi, M. Cesarini, E. Gatto

P_213 **A long-term effect of miglustat on Niemann-Pick type C: An 8-years follow-up of dystonia and ataxia**

J.W. Kim

P_214 (GPT) **Another Common Genetic Ataxia in South Korea: Spinocerebellar ataxia 36**

J. Youn, J.H. Ahn, Y. Han, H. Chang, J. -H. Jang, J. W. Cho

P_215 **Correlation of age onset and Mitochondrial DNA haplogroup in Indian Spinocerebellar ataxia type 2 (SCA2) patients**

A.K. Sonakar, M.V.P. Srivastava, M. Faruq, A.K. Srivastava

Tremors, Myoclonus

P_216 **A genetic pearl for counseling patients with SGCE positive myoclonus-dystonia**

A. Higinbotham, C. Kilbane

P_217 **The Cameraperson Sign in the Diagnosis of Functional Tremor**

E. Assaedi, J. Siddiqui, U. Shuaib

P_218 (GPT) **A Case Series of Essential Tremor Featuring Rest Tremor of the Lower Extremities**

E. Tamadonfar, J. Chan, X. Mason

P_219 **Essential1: Results from a Phase 2 trial evaluating the tolerability, safety, and efficacy of ulixacaltamide in adults with essential tremor**

M. Giroux, G. Wright, H. Jacotin, J. Zhao, M. Sniecinski, A. Samaroo, C. Griffin, A. La Croix, R. Able, C. Santos, M. Souza, on behalf of the Essential1 Study Team

P_220 **Atypical midbrain head tremor presenting as like Bobble-head doll syndrome after successful brain surgery of hemorrhagic cavernous hemangioma.**

W.T. Yoon

P_221 **Accelerometric quantification of FTM tremor measurements in ET patients: a pilot study**

A. Smid, R.W.J. Pauwels, J.W.J. Elting, C.S.J. Everlo, J.M.C. van Dijk, T. van Laar, K. Tamasi, A.M.M. van der Stouwe, G. Drost

P_222 **Burden of Essential Tremor: Associated Morbidities, Healthcare Resource Utilization and Costs in Commercially Insured Patients on Drug Therapy**

L. Hennum, D. Khosla, A. Samiian

- P_223 **A phase 2b, randomized, dose-response study of SAGE-324/BIIB124 for the treatment of essential tremor: KINETIC 2 trial in progress**
R. Pahwa, A.L. Ellenbogen, D. Arkilo, T. Dam, T. Lieu, B. Hersh, M. Qin, S. Garafola, M.E. Gerbasi, H. Colquhoun
- P_224 **Transcutaneous afferent patterned stimulation (TAPS) of the median-ulnar nerves may offer greater tremor relief than median-radial TAPS: A pilot study**
M. Ozturk, C. Charlebois, V. Vargas, A.R Kent
- P_225 **Clinical effectiveness of transcutaneous afferent patterned stimulation therapy for essential tremor in a real-world setting: a randomized pragmatic trial**
D. Dai, J. Fernandes, H. Coetzer, V. Zraick, H. Kim, L. Hennum, K. Rosenbluth
- P_226 **Reduced cerebellar volume and preserved white-matter integrity in Essential Tremor: a UK Biobank nested case-control study**
X. Mason, E. Haddad, N. Jahanshad

Gait Disturbances and Other Movement Disorders

- P_227 **Trazodone-Associated Parkinsonism with Tremor: a Case Series and Literature Review**
D. Desai, S. Desai, H. Chovatiya
- P_228 **The spectrum of phenomenology in painful leg and moving toes syndrome (PLMT): a way towards creating diagnostic criteria**
E. Gray, K. Frei
- P_230 **Restless limb syndrome and insomnia: co-morbidities in rural Indian migraine patients**
D. Desai, M. Solanki, S. Desai
- P_231 **Anticholinergics should not be used to treat tardive dyskinesia: insights from an expert panel of psychiatry and neurology healthcare professionals**
E. Jen, N. Vanegas-Arroyave, D. Vanderhoef, R. Manahan, S. Cicero
- P_232 **Relationship between frontal lobe dysfunction and fear of falling in people with Parkinson's disease**
Y. Yamaguchi, S. Fujioka, K. Kitano
- P_233 **A follow-up study of Diffusion Tensor Imaging after ventricular shunt in a patient with Idiopathic Normal Pressure Hydrocephalus**
X. Yuan, J. Chen, Y. Zhou, X. Zhang, Z. Li, Y. Tang
- P_234 **Prevalence and Impact of Restless Legs Syndrome in patients with stroke in a rural medical teaching hospital in India**
S. Desai, J. Darji, D. Desai
- P_235 **Does the Preoperative iNPH Radscale Predict Clinical Outcomes Post-Ventriculo-peritoneal Shunt Placement (VPS) in Patients with Normal Pressure Hydrocephalus (NPH)?**
D. Ghosh, P. Gilson, A. Kundrick, B. Baugher, J. Liao, C. Sonneborn, O. Hogue, C. Fellows, P. Salles Gandara, H.H. Fernandez, S. Nagel
- P_236 **Expanding the phenotypic spectrum of CSF1R variant carriers**
J. Nowak, J. Dulski, Z. Wszolek
- P_237 (GPT) **Predictors of bone marrow transplant outcomes in CSF1R-related adult-onset leukoencephalopathy with axonal spheroids and pigmented glia**
J. Dulski, M. Heckman, L. White, K. Zur-Wyrozumska, T. Lund, Z. Wszolek
- P_238 (GPT) **Differences in patient and healthcare professional perspectives on the key impacts of tardive dyskinesia**
S. Finkbeiner, S. Leo, D. Goldschmidt, R. Ayyagari, E. Hagopian, K. Sarathy, I. Nason, R. Jain

- P_239 (GPT) **A novel C19ORF12 mutation in two MPAN sisters treated with deferiprone**
S. Chen, X. Lai, J. Fu, J. Yang, B. Zhao, H. Shang, x. Chen
- P_240 **Subcortical, Limbic, and Neocortical Dopaminergic Innervation Determines response to Levodopa in older adults with slow walking and Minimal Parkinsonian Signs**
R. Paalanen, S. Roytman, M. van Emde Boas, C. Pongmala, P. Kanel, N. Bohnen, C. Rosano
- P_241 **The clinician's tardive inventory (cti): an integrated phenomenological and functional measure of tardive dyskinesia**
R. Trosch, C. Comella, S. Caroff, W. Ondo, A. Shillington, B. LaChappelle, R. Hauser, C. Correll, J. Friedman
- P_242 (GPT) **Real-world adherence to deutetrabenazine or valbenazine among patients with tardive dyskinesia**
S. Finkbeiner, S. Leo, V. García-Horton, S. Zhang, R. Ayyagari
- P_243 **Sustained treatment response with long-term valbenazine in patients with tardive dyskinesia**
C. Zinger-Salmun, C.U. Correll, J.-P. Lindenmayer, K. Farahmand, E. Jen, S. Siegert, E. Dunayevich
- P_244 **Gait during turning associates with imbalance and falls in PD: 3D Video based analysis from a single camera**
J. Hwan Shin, H. Young Jeon, B. Jin, S.-M. Lee, S. Yeon Kim, K. Ah Woo, H.-J. Kim, B. Jeon

Rehabilitation, Nursing/Physiotherapy, Other Allied Health; Patient Participation

- P_245 **Outcome measurement and goal-setting recommendations in the multipattern treatment of shoulder spasticity with botulinum neurotoxin**
J. Jacinto, A. Camões-Barbosa, S. Carda, D. Hoad, J. Wissel
- P_246 **Feasibility of Parkinson's disease treatment utilizing therapy dog with American Kennel Club Canine Certified Therapy Dog**
A. Durbin, A. Scheurer, J. Brasic
- P_247 **Maintaining and improving individual gains made in physical therapy (PT) by using a dynamic standing protocol post-physical therapy sessions**
M. van Emde Boas, C. Pongmala, A. Griggs, N.I Bohnen
- P_248 (GPT) **Pharyngeal structure and dysphagia in patients with Parkinsonism**
J. Lee, S.H. Ohn
- P_250 **Functional Outcomes of an Intensive Multimodal Rehabilitation Intervention for Moderately Advanced Parkinson's Disease**
P. Moondra, A. Persaud, M. McCrossin, C. Claro, L. Rubin, A. Di Rocco
- P_251 **Virtual Reality Table Tennis in People with Parkinson Disease**
S. Fujioka, K. Nagaki, J. Takami, K. Kimura, K. Inoue, K. Kitano, H. Kikuchi, Y. Tsuboi
- P_252 (GPT) **Combined physiotherapy and deep brain stimulation to improve independent community mobility in Parkinson's disease**
R. Rajalingam, G. Sorrento, Y. Felloni, J. Goldstein Elman, R. Zaidlin, K. Musselman, C. Marras, A. Fasano
- P_253 (GPT) **Effects of Aerobic Exercise on Motor and Non-Motor Symptoms of Parkinson's Disease: A Systematic Review and Meta-Analysis**
M. Elfaituri, T. Khaled, H. Faraj

INFORMATION FOR ABSTRACT AUTHORS

Posters and guided poster tours of the IAPRD 2023 Congress will be located in room W196c. The poster exhibition is open to all participants according to the opening times indicated in the daily program overview.

The poster size is 46,8 inch high and 33,1 inch wide, DIN A0 (portrait format).

Set-up times for posters / oral posters

Saturday, 13 May 2023 11:00 – 19:00

Dismantling

Monday, 15 May 2023 17:00 – 18:00

Posters which have not been removed within the indicated time schedule will be removed and disposed.

Guided Poster Tours

Please note that the time allocated for your presentation is a short 2-minute oral presentation in the English language plus Q&As. Due to the reason that there will be further presentations, we urge you not to exceed the time limit in order to give the other speakers time for their talks.

The Guided Poster Tours will take place as a poster walk chaired by renowned specialists. Interested delegates can meet the authors during the time of the Guided Poster Tours. The presentation will be directly at your poster.

INFORMATION FOR SPEAKERS AND CHAIRPERSONS

Please be at your session room at least 15 minutes prior to the start of your session. Please note that your speaking time, as indicated in the email correspondences, has to be strictly followed. If you are not certain about the assigned speaking time, please contact your session coordinator, or Jasmin Greger at the registration desk.

TRAVEL GRANTS

The IAPRD acknowledges the generous support of the Parkinson's Foundation, which has provided funding for deserving trainees in the field of movement disorders to attend this congress.



The awards are aimed at promoting participation in the Congress by young researchers worldwide, under the age of 35. The deadline for Travel Grant applications was 26 February 2023.

Further information is available on the congress website.

INDEX OF AUTHORS AND SPEAKERS

A

Abdelwahab Elshourbagy23
 Ai Huey Tan19
 Ailton Melo18
 Alberto Albanese 15, 17, 18
 Alfonso Fasano19
 Andreas Puschmann21
 Angelo Antonini 17, 29
 Anhar Hassan 22, 26
 Ankush Kumar15
 Anne-Marie Wills 23, 26
 Arunmozhimaran Elavarasi26
 Ashley Durbin26

B

Bas Bloem 17, 18
 Benjamin Grimm25
 Benjamin Walter 17, 24
 Benoit Tas23
 Beom Seok Jeon 16, 18
 Bettina Balint 19, 26

C

Caroline Tanner11
 Chad Heatwole15
 Christine Klein21
 Claire Henchcliffe25
 Cristina Sampaio12
 Cynthia Comella 11, 12

D

Daniel Kremens 18, 27
 Daniel Martinez-Ramirez 23, 27
 Daniel Truong 11, 12
 Dan Weintraub17
 Danyu Lin22
 David Charles16
 Deborah Hall 11, 29
 Diego Torres-Russotto 24, 25, 29
 Dirk Dressler27
 Drew Kern16

E

Elan Louis18
 Elena Moro 15, 29
 Emily Tamadonfar25
 Etienne Hirsch 12, 22

F

Farwa Ali17
 Fereshte Adib Saberi25

G

Genko Oyama15

H

Hash Brown Taha22
 Henry Mauricio Chaparro-Solano21
 Horacio Kaufmann26
 Hubert Fernandez 11, 12, 16, 29
 Huifang Shang29
 Hyder Jinnah27

I

Ioannis Isaias29
 Irene Litvan26

J

Jamison Seabury16
 Janine Chan25
 Janis Miyasaki29
 Jan Roth11
 Janvi Ramchandra23
 Jaroslaw Dulski 15, 16, 21, 24
 Jaroslaw Sławek 19, 27
 Jeff Elias15
 Jeongeun Lee 21, 29
 Jie Ping Schee24
 Jinyoung Youn 24, 25
 Joaquim Ferreira18
 John O'Brien26
 Jon Stoessl18
 Joohi Jimenez-Shahed 11, 17, 29
 Joseph Friedman27
 Julian Fernandez Boccazzi25
 Junaid Siddiqui24
 Junyu Lin15

K

Kai-Cheng Hsu23
 Kailash Bhatia 16, 26
 Karen Frei 12, 23, 27
 Karina Burda25
 Katerina Markopoulou16
 Khang Chung Ngoc Vo21
 Kruzette Khloe Solijon26

L

Leo Verhagen 15, 21, 29
 Lobarkhon Alimbekova22
 Lorraine Kalia12

M

Madeline Kroeger23
 Madison Butler21
 Maria Belen Justich15
 Marie-Helene Saint-Hilaire 12, 21, 25, 30
 Marissa Dean12
 Mark Hallett26
 Mark Lew 11, 22
 Massimiliano Passaretti16
 Melissa Jo Armstrong17
 Min Seung Kim23
 Mohamed Abulfadl22
 Monica Arena24
 Muhammed Elfaituri24


N

Natalia Madetko-Alster23
 Natalia Szejko 16, 23
 Niccolo Mencacci15
 Nicolaas Bohnen17

O

Oday Halhouli26
 Oksana Suchowersky25
 Olaia Lucas-Jiménez24
 Oliver Phillips24

P	Thien Thien Lim	26
Pardeep Kumar	Thi Huyen Thuong Dang	22
Pavnit Kukreja	Todd Levine	22
Peter Hedera	Tucker Tomlinson	16
Philippe Salles-Gándara	U	
Philip Tipton	Un Kang	18, 23, 25
Pramod Pal	V	
Prashant Natteru	Viviana Torres	16
Q	Vladimira Vuletić	22
Qirui Jiang	W	
R	William Ondo	11
Raja Mehanna	Y	
Rajasumi Rajalingam	Yaroslau Compta	18
Raul Martinez-Fernandez	Z	
Raymond Rosales	Zbigniew K. Wszolek	12, 21
Robert Hauser	Zoltan Mari	27
Ron Pfeiffer		
Ross Elizabeth Cortes		
Rupam Borgohain		
Ruth Walker		
Ruwei Ou		
Ryan Uitti		
Ryuji Kaji		
S		
Sarah Pirio Richardson		
Serge Przedborski		
Shawn Sedgh		
Shilpa Chitnis		
Shinsuke Fujioka		
Sihui Chen		
Simon David		
Simon Lewis		
Soaham Desai		
Stacy Finkbeiner		
Stuart Isaacson		
Surabhi Dharmadhikari		
T		
Talene Yacoubian		
Tanya Simuni		
Tarek Bellaj		
Teus van Laar		



GENERAL CONGRESS INFORMATION

REGISTRATION

Registration Counter

The registration counter is located in the foyer in front of room W190, Level 1.

Opening hours

Saturday, 13 May 2023	08:00 – 19:30
Sunday, 14 May 2023	07:30 – 18:30
Monday, 15 May 2023	07:30 – 17:45
Tuesday, 16 May 2023	07:30 – 12:30

Registration Fees

Registration Types	On-site Price
Regular Congress Ticket	€ 695,00 approx. \$ 729
Reduced Fee**	€ 420,00 approx. \$ 440
Student Ticket***	€ 150,00 approx. \$ 160
Allied Health Professionals	€ 520,00 approx. \$ 545

The registration fees will be charged in € for all attendees. The \$ fees listed above are used for orientation purposes only. They are subject to change according to the current exchange rate during the time of registration.

**Participants from lower & lower middle income countries: List according to WHO criteria on our website.

*** **Students:** Copy of student ID required | **Residents/Fellows/Trainees:** Born after 13 May 1988 and/or still in training. Copy of official document indicating age or a letter stating training status by employer required.

The registration fee for delegates includes:

- Access to the scientific sessions
- Access to the exhibition
- Certificate of attendance
- Printed copy of the scientific program
- Networking reception on Saturday, 13 May 2023 and daily coffee breaks

Name badge

All participants are requested to wear their name badges at all times during the congress. For organizational and security reasons, we request that all participants and exhibitors wear their badges at all times during congress activities.

A barcode is printed on each name badge. This may be scanned by exhibitors/supporters to access your name, affiliation, country, email address and professional interests provided by you when registering for the congress. We would like to point out that this is entirely voluntary and not compulsory for the participation in corporate events.

Delegates can refuse to be scanned at any time. By permitting an exhibitor or supporter to scan your badge, you agree that these details may be used by the company to contact you with relevant product information.

Badges will be colour-coded as follows:

 Member	 Executive Committee
 Faculty	 Fellowship Directors
 Exhibitors	

CME ACCREDITATION

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Amedco LLC and the International Association of Parkinsonism and Related Disorders (IAPRD). Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

Physicians (ACCME) Credit Designation

Amedco LLC designates this live activity for a maximum of 22.50 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

International CME Accreditation

The American Medical Association has determined that physicians not licensed in the US who participate in this CME activity are eligible for *AMA PRA Category 1 Credits™*.

ACCME/AMA PRA Category 1 Credits™ carry reciprocity with EACCME member countries and most international licensing bodies for physicians, with some exceptions. Physicians should check with their country/board for eligibility.

The UEMS-EACCME and the AMA has a signed agreement of mutual recognition of CME credits between Europe and USA for live and e-learning activities. A list of active agreements can be found here <https://eaccme.uems.eu/Agreements.aspx>.

CME ACCREDITATION

The EACCME® has signed agreements with the following countries:

Austria, Armenia, Belgium, Bulgaria, Croatia, Cyprus, Finland, Georgia, Greece, Hungary, Ireland, Regione Lombardia, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Tunisia, Turkey, United Kingdom

Saturday, 13 May 2023	6,25 Credits
Sunday, 14 May 2023	6,00 Credits
Monday, 15 May 2023	6,50 Credits
Tuesday, 16 May 2023	3,75 Credits

Certificate of Attendance

To obtain CME accreditation, please complete the CME evaluation form via the following link: <http://iaprd.cmecertificateonline.com/>. The CME certificate will be available for download after completion of the evaluation.

CONGRESS VENUE

McCormick Place
West Building
2301 S King Dr,
Chicago, IL 60616

How to get there:

Arriving by plane:

Chicago O'Hare International Airport is located 30 minutes away from McCormick Place. All major international airlines serve Chicago, and there are direct oversea flights.

The CTA "L" trains provide service to Downtown Chicago and McCormick Place.

From O'Hare International Airport: The CTA "Blue" line provides service to and from the airport.

Take the Blue Line from O'Hare and transfer to a south-bound Green Line train at Clark and Lake.

Note, in the Loop the Blue Line is a Subway Train and the Green Line is an elevated train, a free transfer is available at Clark and Lake.

The Cermack-McCormick Place Station is 2 block (0.15 miles) walk from the Northwest Corner of the McCormick Place West Building.

Arriving by train - Public transportation from Downtown Chicago:

Located on Level 2.5 of the Grand Concourse in the South Building, the METRA Electric commuter railroad provides direct service within seven minutes to and from downtown Chicago. Service from the Millennium (Randolph St.) Station (near the Fairmont Hotel) to McCormick Place begins early morning, with more frequent pick-ups during rush hours.

The distance between McCormick Place South Building and McCormick Place West Building is 0.8 miles.

Public transportation

The #3 King Drive bus is the most common bus route to McCormick Place as it runs north/south along Michigan Avenue serving many downtown hotels and the Magnificent Mile and Water Tower Place. The McCormick Place stop is located at 2301 Dr. Martin Luther King Jr. Drive, Chicago and is in front of our main entrance.

Arriving by car:

There are three main parking lots on the McCormick Place campus. All are in close proximity and walking distance to our convention complex and are ADA accessible.

Attendees for IAPRD designate Lot A as the primary parking location.

Networking Events

Welcome Reception

Saturday, 13 May 2023

Time: after the Opening Ceremony

The Welcome Reception on Saturday evening is the place to connect with other experts and colleagues from around the globe. Please join us at this informal get-together to greet old friends, meet new colleagues, and exchange impressions of the Congress. Enjoy traditional light snacks and beverages in the casual atmosphere of McCormick Center.

Ticket: Included in Registration Fee

Abstracts

The Online Abstract book contains all accepted abstracts that have been submitted by authors from around the globe on topics related to Parkinson disease and other movement disorders and is available only for the duration of the congress on the congress website. All abstracts have been reviewed by a panel of reviewers and is now provided as download.

Climate

Chicago's climate is **typically continental** with cold winters, warm summers, and frequent short fluctuations in temperature, humidity, cloudiness, and wind direction. In May the average temperature is 19°C/68°F.

Cloakroom

A cloakroom is located in W195. You can also store your luggage there.

Coffee breaks

Coffee and tea is provided during the breaks in the exhibition area and gratefully supported by CND Life Science.

Currency

The official currency is US Dollar (USD). Exchange of foreign currency is available at the airport, train station, at most hotels, banks and exchange offices.

Disclaimer

The Organizers cannot accept liability for injuries or losses of whatever nature incurred by participants, nor for loss of or damage to their luggage and/or personal belongings.

Language

The official language of the International Association Parkinsonism and Related Disorders is English. However, all participants are encouraged to join discussions regardless of their fluency in English, as the exchange of ideas and critical evaluation of presentation is the main purpose of the entire Congress.

Mobile phones

Participants are kindly requested to keep their mobile phones turned off while attending the scientific sessions.

Personal Insurance

We recommend that all participants take out a personal travel and health insurance for their trip.

Press

Journalists should bring their press ID and register at the congress registration counter.

Program Changes

The Organizers cannot assume liability for any changes in the program due to external unforeseen circumstances.

Recording

Cameras, video cameras or audio recording devices are not permitted in the session rooms. Any recording/documentation of sessions is strictly forbidden.

Safety

As in all major cities and congress venues, people should take care of their personal belongings. It is not advised to wear your congress badge outside the XXVIII IAPRD Congress activities. Especially in touristic hotspots please be aware of pickpockets.

Smoking Policy

Smoking is not allowed at the venue; the meeting is a non-smoking event.

Wi-Fi and Social Media

Wi-Fi

Complimentary Wi-Fi access is available throughout the venue.

SSID IAPRD2023

Password: Congress

Social Media




Twitter: Follow us @PRDAssociation

Follow us @ParkinsonismD



LinkedIn: IAPRD Secretariat



IAPRD

About the International Association of Parkinsonism and Related Disorders

More than fifty years ago, the **International Association of Parkinsonism and Related Disorders** was established by the World Federation of Neurology to promote and monitor research developments, as well as to foster communication among neuroscientists in the field. Today, this association is an international, professional association of clinicians, scientists and other healthcare professionals who are interested in neurodegenerative disorders like Parkinson's disease, secondary parkinsonisms, hyperkinetic and hypokinetic movement disorders, and more generally any disorder affecting muscle tone and motor control. The most common clinical disorders and/or symptoms of interest to us are:

- Genetic and idiopathic Parkinson's disease and other parkinsonism
- Genetic and idiopathic disorders with dystonia
- Huntington's disease and other disorders with chorea
- Cerebellar disorders
- Tremor, myoclonus, tics, ballism
- Huntington's disease, chorea and Gilles de la Tourette's syndrome
- Psychogenic and psychiatric movement disorders
- Movement disorders-related non-motor disorders, such as disorders of the autonomic nervous system, mood disorders, sleep disorders (including: excess daytime sleepiness, REM sleep behaviour disorders, restless legs syndrome, and periodic limb movements) and psychiatric disorders (including: Impulse control disorders, executive dysfunction, dementia, delusions and hallucinations).

The IAPRD has associate members, full members, and honorary members.

Further information is available at www.iaprd.info



IAPRD 2023 Lifetime Achievement Award

Dr. Stanley Fahn

BIOGRAPHICAL SKETCH OF STANLEY FAHN, MD

Stanley Fahn, MD, is the H. Houston Merritt Professor Emeritus of Neurology and Director Emeritus of the Center for Parkinson's Disease and Other Movement Disorders at Columbia University in New York City, from which he retired in 2021 after nearly 60 years of teaching, research, and patient care. Dr. Fahn served as President of the American Academy of Neurology (AAN) from 2001 to 2003, the Scientific Director of the Parkinson's Disease Foundation from 1979 until 2016, and the first president of the Movement Disorder Society, which he cofounded with Dr. David Marsden. He also co founded the journal *Movement Disorders* and served as co-editor for 10 years, in addition to serving as associate editor of the journal *Neurology* for 10 years. Dr. Fahn served twice as chairman of the Advisory Committee on Peripheral and Central Nervous System Drugs for the Food and Drug Administration. With Dr. Ira Shoulson, Dr. Fahn co founded the Parkinson Study Group (PSG), a consortium of clinical investigators dedicated to conducting controlled clinical trials on the prevention and treatment of Parkinson disease. Dr. Fahn served as co-chair of its Executive Committee for 20 years and participated in many clinical trials of Parkinson's disease therapeutics, including the ELLDOPA trial

that studied the effect of levodopa therapy on the natural history of Parkinson's disease, published in 2004 in the *New England Journal of Medicine*. For this work, he was co-winner of the triennial Anne-Marie Opprecht Foundation Parkinson Award in 2005 for the most outstanding scientific work on Parkinson's disease published in the years 2002-2004.

In dystonia, Dr. Fahn founded and directed the first Dystonia Clinical Research Center in the United States. This Center was responsible for determining the autosomal dominant inheritance pattern of childhood-onset torsion dystonia and for mapping several genes for this disorder.

Dr. Fahn has received numerous awards from neurological organizations, including, from the AAN, the Robert Wartenberg Award for outstanding clinical research in 1986, the A. B. Baker Award for outstanding educator in neurology in 1996, and the first Movement Disorder Prize for outstanding contributions in 1997. The American Neurological Association awarded him the first Soriano Lectureship for excellence in research. The Movement Disorder Society presented him with its President's Distinguished Service Award in March 2005, and he was awarded the Jay Van Andel Award for Outstanding Achievement in Parkinson's Disease Research from the Van Andel Research Institute in 2016. Dr. Fahn has also received many awards from lay foundations, including the James Parkinson Medal, awarded once every 10 years by the Parkinson's Disease Foundation.

In 2002, Dr. Fahn was elected a member of the Institute of Medicine of the US National Academies (now the National Academy of Medicine). September 2007 saw the publication by Elsevier of a textbook on movement disorders titled *Principles and Practice of Movement Disorders*, which he co-authored with Dr. Joseph Jankovic. The second edition was published in 2011, with Dr. Mark Hallett joining as a third author. Dr. Fahn has trained more than 130 movement disorder fellows, including many who are professors of neurology around the globe.

IAPRD 2023 Melvin Yahr Award

Prof. Dr. Vincenzo Bonifati

Award Lecture:

Deciphering the genetic code of movement disorders

Saturday, 13 May 2023, 17:15 – 19:00

Session: Opening Ceremony / IAPRD Lifetime Achievement Award / Melvin Yahr Lecture

Vincenzo Bonifati received his MD and neurology certification from the University of Roma, Italy. After many years of clinical work dedicated to patients with Parkinson's disease and other movement disorders, in 2000 he moved to the Erasmus University Rotterdam, The Netherlands, where in 2003 he received his PhD in human molecular genetics, and was later appointed as Associate Professor and, since 2012, Full Professor in *Genetics of Movement Disorders*.

His research focuses on elucidating the molecular mechanisms of Parkinson's disease and other movement disorders, by the identification of disease-causing genetic variants and the characterization of their molecular pathways.

His work led to the discovery of the genetic defects underlying several forms of hereditary parkinsonism, dystonia, and other movement disorders.

He published more than 230 papers in peer-reviewed journals, and has an H-index of 67. His work has been cited more than 19,000 times so far. (source: Scopus)

He is co-Editor-in-Chief of *Parkinsonism & Related Disorders*, and has served as Councilor of the International Association of Parkinsonism and Related Disorders (IAPRD). He also served as the Chair of the Congress Scientific Program Committee of the International Parkinson and Movement disorder Society (MDS, 2020-2021).

IAPRD COMMITTEES

Scientific Program Executive Committee (SPEC)

Rajesh Pahwa, Chair (USA)
Marie-Helene Saint-Hilaire (USA)
Shinsuke Fujioka (Japan)
Karen Frei (USA)
Cynthia Comella (USA)
Huifang Shang (China)
Diego Torres-Russotto (USA)

Alberto Albanese (Italy)
Hubert Fernandez (USA)
Ioannis Isaias (Germany)
Andreas Puschmann (Sweden)
Tanya Simuni (USA)
Claire Henchcliffe (USA)

Scientific Program Committee (SPC)

Zbigniew Wszolek (USA)
Joachim Krauss (Germany)
Janis Miyasaki (Canada)

Anhar Hassan (USA)
Tiago Mestre (Canada)

Awards Committee

Ronald Pfeiffer, Chair (USA)
Erik Wolters (Netherlands)
Alberto Albanese (Italy)
Mohit Bhatt (India)
Jonathan Carr (South Africa)

Robert Rodnitzky (USA)
Carolyn Sue (Australia)
Marie Vidailhet (France)
Ai Huey Tan (Malaysia)

Abstract Review Committee

Shinsuke Fujioka, Chair (Japan)
Katerina Markopoulou, Co-Chair (USA)
Luca Marsili (USA)
Jinyoung Youn (Republic of Korea)
Richard Trosch (USA)
Vladimira Vuletic (Croatia)
Zoltan Mari (USA)
Philippe Salles (Chile)
Yevgen Trufanov (Ukraine)
Roberto Erro (Italy)
Daniel Martinez-Ramirez (Mexico)

Sanjay Pandey (India)
Hana Brozova (Czech Republic)
Elan Louis (USA)
Maria Fiorella Contarino (The Netherlands)
Yoshitaka Yamanaka (Japan)
Pawel Tacik (Germany)
José Fidel Baizabal Carvallo (Mexico)
Pattamon Panyakaew (Thailand)
Michelle Tosin (USA)
Abhi Mahajan (USA)

Industry Liaison Committee Members


Karen Frei, Co-chair (USA)
Marie-Helene Saint-Hilaire, Co-chair (USA)
Alberto Albanese (Italy)
Mark Lew (USA)
Raja Mehanna (USA)

Elena Moro (France)
Joohi Jimenez-Shahed (USA)
Heinz Reichmann (Germany)
Hubert Fernandez (USA)
Stuart Isaacson (USA)

World Congress Ambassador Committee

Helio Teive; Laura Silveira (Brazil)
Philippe Salles Gándara (Chile)
Huifang Shang (China)
Oscar Bernal Pacheco; Xiomara Garcia (Colombia)
Vladimira Vuletić (Croatia)
Pawel Tacik (Germany)
Frandy Susatia (Indonesia)
Shinsuke Fujioka; Genko Oyama (Japan)
Beomseok Jeon (Korea, South)
Thien Thien Lim; Ai Huey Tan (Malaysia)
Daniel Martinez-Ramirez (Mexico)
Lara Oyatoye (Nigeria)
Gabriela Novotni (North Macedonia)
Mathias Toft (Norway)

Gerard Saranza (Philippines)
Cristian Falup-Pecurariu (Romania)
Igor Petrovic (Serbia)
Peter Valkovič (Slovakia)
Maja Trošt (Slovenia)
Yaroslau Compta (Spain)
Per Svenningsson (Sweden)
Pattamon Panyakaew (Thailand)
Gencer Genc (Turkey)
Yevgen Trufanov (Ukraine)
Shivam Om Mittal (United Arab Emirates)
Valentina Leta (United Kingdom)
Tai Tran (Vietnam)



INDUSTRY


This event is supported, in part, by funding from industry. All support is managed in strict accordance with CME/AMA accreditation criteria and standards for commercial support. This section contains information that is promotional in nature, distinct from the scientific/educational elements of the main CME/CPD event.

EXHIBITION FLOOR PLAN

Code of Transparency

Interplan publishes the conditions and the scope of the support provided by EFPIA member companies to the IAPRD Congress on a voluntary basis. The publication will be carried out before and during the execution of the Congress.

For the industry partners mentioned above, we are herewith informing about their overall support within the framework of the IAPRD Congress 2023.



Company

AbbVie Inc.
 AbbVie US Medical Affairs
 Acorda Therapeutics, Inc.
 Amneal Pharmaceuticals LLC.
 Avion Pharmaceuticals
 CND Life Sciences
 GE Healthcare
 Great Lakes NeuroTechnologies
 Kyowa Kirin, Inc.
 Neurocrine Biosciences, Inc.
 Neurocrine Biosciences Medical Affairs
 Supernus Pharmaceuticals, Inc.
 Sage Therapeutics, Inc.

Booth No.

14 | 16
 01
 13
 02
 11
 15
 05
 10
 17
 12
 06
 03
 04

Exhibition Opening Times

Saturday, 13 May 2023
 15:00 – 20:00

 Sunday, 14 May 2023
 09:00 – 17:00

 Monday, 15 May 2023
 09:00 – 17:00

SPONSORS AND SUPPORTERS

We kindly thank all our sponsors for their support!
Sponsor names are in alphabetical order.



Coffee breaks:

The coffee breaks are kindly supported by:



Saturday, 13 May 2023



Corporate Lunch Session

Plenary Room W196

12:45 – 13:45

Corporate Lunch Session: Acadia Pharmaceuticals Inc

A Focused Approach to the Management of Hallucinations and Delusions Associated With Parkinson's Disease Psychosis

12:45 – 13:00

Review educational information about hallucinations and delusions associated with Parkinson's disease (PD) psychosis

Speaker: *Laxman Bahroo (Washington DC, United States)*

13:00 – 13:20

Review clinical efficacy and safety of a treatment option for hallucinations and delusions associated with PD psychosis

Speaker: *Laxman Bahroo (Washington DC, United States)*

13:20 – 13:30

Discuss real-world evidence

Speaker: *Veronica Clark (Buntingford, United Kingdom)*

13:30 – 13:45

Q&A

Sunday, 14 May 2023



Corporate Lunch Session

Room W194b

12:15 – 13:45

Corporate Lunch Session: Supernus

Increasing GOOD ON Time while reducing OFF and dyskinesia in patients with Parkinson's disease

12:15 – 13:15

Increasing GOOD ON Time while reducing OFF and dyskinesia in Parkinson's disease

Speaker: *Robert Hauser (Tampa, United States)*

Speaker: *William Ondo (Houston, United States)*

13:15 – 13:45

Q&A

Speaker: *Robert Hauser (Tampa, United States)*

Speaker: *William Ondo (Houston, United States)*



Corporate Lunch Session

Room W192a

12:15 – 14:15

Corporate Lunch Session: Merz Therapeutics

Hands-On Ultrasound Course

Merz Therapeutics is pleased to invite residents, fellows, and early-career physicians to an expert-guided ultrasound course for cervical dystonia and sialorrhea. This course is designed to provide additional confidence with ultrasound-guided muscle localization for botulinum toxin injections. Participants will benefit from a small-group learning environment led by expert faculty, and each participant will receive significant hands-on time targeting muscles with ultrasound.



Corporate Lunch Session

Plenary Room W192b

12:15 – 13:45

Corporate Lunch Session: Neurocrine Biosciences, Inc.

Exploring the Science, Symptoms, and Treatment of Hypo- and Hyperkinetic Movement Disorders- ONGENTYS (Opicapone) capsules for PD and INGREZZA (Valbenazine) capsules for TD

Speaker: *Daniel Kremens (Philadelphia, United States)*

Speaker: *Richard Trosch (Oakland, United States)*

12:15 – 12:35

Identifying disease-specific features for patients presenting with one or multiple types of movement disorders

12:35 – 12:55

Discussing the shared pathophysiology of dopamine-associated hyper and hypokinetic movement disorders

12:55 – 13:15

Review clinical study data for an FDA-approved adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing OFF episodes

13:15 – 13:35

Review clinical study data for FDA-approved treatment for adults with tardive dyskinesia, including a before and after patient case

13:35 – 13:45

Q&A

Monday, 15 May 2023



Corporate Lunch Session

Plenary Room W196

12:15 – 13:45

Corporate Lunch Session: Abbott

DBS Hands-on Training: Harnessing the Power of Remote Programming

12:15 – 12:50

The Power of Remote Programming in Deep Brain Stimulation Patients

Speaker: *Leo Verhagen (Chicago, United States)*

12:50 – 13:25

Hands-on Training for Deep Brain Stimulation Programming

Speaker: *Xenos Mason (Los Angeles, United States)*

13:25 – 13:45

Q&A



Corporate Lunch Session

Room W194b

12:15 – 13:45

Corporate Lunch Session: Merz Therapeutics

Understanding Adult Chronic Sialorrhea: the impact on patients & using ultrasound guidance with Incobotulinumtoxin-A injection treatment

This will be a 90-minute presentation exploring the underdiagnosed condition of adult chronic sialorrhea, the impact to the patient/caregiver and how ultrasound guided treatment with incobotulinumtoxinA injections can help improve patient outcomes. Hosted by Merz Therapeutics.

Moderated by expert faculty, Dr. Stuart Isaacson*, Dr. Fernando Pagan* and Dr. Daniel Kremens*, this collaborative session will feature demonstrations on the use of ultrasound guidance when injecting with botulinum toxin.

* Dr. Isaacson, Dr. Pagan & Dr Kremens are paid consultants of Merz Pharmaceuticals, LLC.

Speaker: *Stuart Isaacson (Boca Raton, United States)*

Speaker: *Fernando Pagan (Washington DC, United States)*

Speaker: *Daniel Kremens (Philadelphia, United States)*



Corporate Lunch Session

Room W192b

12:15 – 13:45

Corporate Lunch Session: AbbVie

Challenges in Recognizing the Hidden Burden of Advancing PD and What Can Be Done

12:15 – 12:20

Welcome and Objectives

Speaker: *Joohi Jimenez-Shahed (New York City, United States)*

12:20 – 12:30

PD: How our understanding of etiology may inform treatment decisions

Speaker: *Joohi Jimenez-Shahed (New York City, United States)*

12:30 – 12:40

PD from Patient and Caregiver Perspectives

Speaker: *Joohi Jimenez-Shahed (New York City, United States)*

12:40 – 12:50

Treatment considerations as PD advances

Speaker: *Joohi Jimenez-Shahed (New York City, United States)*

12:50 – 13:05

Early identification of advancing PD

Speaker: *Joohi Jimenez-Shahed (New York City, United States)*

13:05 – 13:15

Q&A

MERZ THERAPEUTICS IS PROUD TO BE A SPONSOR OF **IAPRD 2023**

Everything we do is
in relentless pursuit
of better outcomes
for more patients.

At Merz Therapeutics, we are as
united in our compassion as we are
diverse in our perspectives and
experiences.

Visit MerzTherapeutics.com/US to learn more



THERAPEUTICS

Better outcomes for more patients.

Copyright © 2023 Merz Pharmaceuticals, LLC. All rights reserved.
Merz and the Merz logo are registered trademarks of Merz Pharma
GmbH & Co. KGaA.

Organizer of the scientific conference

IAPRD

IAPRD Secretariat

15403 N. McKinnon Road

Mead, WA USA

E-Mail: machapm@comcast.net

Website: www.iaprd.info



Congress and Exhibition Office

INTERPLAN

Congress, Meeting & Event Management AG

Office Munich

Landsberger Straße 155, 80687 München, Germany

Phone: +49 89 548234-58

E-mail: IAPRD@interplan.de

Website: www.interplan.de



Data Protection

INTERPLAN AG handles all personal data according to the laws of § 4 under the Federal Data Protection Act. For your registration to a congress organized by Interplan, the collecting, saving and processing of your personal data is imperative. This is done solely as a means of the organization and completion of the event. The collected data will only be passed onto a third party, who is directly involved with the running of the congress and when the organizational procedure makes this necessary (operator, hotel, visa, social program etc.).

The legislator requires us to obtain the participant's consent. The registration to a congress organized by us is not possible if we do not get this. When registering you declare the following: I hereby declare my consent that all the information made by me to my person within the handling of the above mentioned congress is filed, saved, processed and the demands made above can correspondingly be passed onto a third party. I agree to receive information on future congresses related to the subject of this event.

Declaration of consent can be retracted at any time by sending a message to Interplan AG, Landsberger Strasse 155, 80687 München, iaprd@interplan.de



Don't miss these Teva-sponsored posters on tardive dyskinesia!

Presented at the Guided Poster Tour on
Monday, 15 May, 09.30 – 10.30 AM



Real-world adherence to
deutetrabenazine or valbenazine
among patients with tardive dyskinesia



Differences in patient and
healthcare professional perspectives
on the key impacts of tardive dyskinesia

Visit
CnsBytes.us for
more content on
movement disorders



©pixabay.com

WORLD CONGRESS ON PARKINSON'S DISEASE AND RELATED DISORDERS

LISBON, PORTUGAL

SAVE THE DATE

2024

19 – 22 May

www.iaprd-world-congress.com

